Track market-moving stories before they get noisy

Crossmark Global Holdings Inc. increased its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 5.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 46,657 shares of the company’s stock after purchasing an additional 2,507 shares during the period. Eli Lilly and Company makes up 0.7% of Crossmark Global Holdings Inc.’s holdings, making the stock its 25th biggest holding. Crossmark Global Holdings Inc.’s holdings in Eli Lilly and Company were worth $53,986,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the stock. Maseco LLP increased its stake in Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after acquiring an additional 28 shares during the last quarter. Marshall & Sterling Wealth Advisors Inc. boosted its holdings in shares of Eli Lilly and Company by 60.0% in the 1st quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock valued at $37,000 after purchasing an additional 15 shares in the last quarter. AlphaCentric Advisors LLC bought a new stake in shares of Eli Lilly and Company during the 1st quarter worth $42,000. Caitlin John LLC bought a new stake in shares of Eli Lilly and Company during the 2nd quarter worth $64,000. Finally, IMG Wealth Management Inc. boosted its stake in Eli Lilly and Company by 500.0% in the second quarter. IMG Wealth Management Inc. now owns 60 shares of the company’s stock valued at $72,000 after buying an additional 50 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Manufacturing expansion supports long-term growth. Lilly broke ground on a $5 billion facility in Goochland County, Virginia, its first U.S. site designed to produce both active pharmaceutical ingredients and finished medicines. The project is part of a more than $50 billion U.S. manufacturing expansion and is expected to create 650 jobs, improving supply capacity for next-generation cancer and other complex medicines. Lilly Richmond manufacturing facility announcement Positive Sentiment: Weight-loss drug demand remains a major growth driver. Analysts expect emerging-market sales of weight-loss drugs to become a significant opportunity, supporting the long-term outlook for Mounjaro, Zepbound and related incretin products. Lilly’s recent growth has been driven by increasing volume, even as pricing has declined. JP Morgan emerging-market weight-loss drug outlook Positive Sentiment: Some analysts are raising earnings expectations. Erste Group Bank increased its FY2027 EPS forecast for Lilly to $47.77 from $47.30, signaling confidence in the company’s longer-term earnings trajectory. Erste Group Bank EPS estimate update Neutral Sentiment: ESG progress may support the company’s reputation but is unlikely to drive near-term trading. Lilly was cited for combining philanthropy with environmental initiatives while maintaining rapid commercial growth. Eli Lilly sustainability leadership article Negative Sentiment: Near-term earnings risk is weighing on sentiment. Previews anticipate a decline in third-quarter earnings, raising concerns that the stock’s elevated valuation leaves limited room for disappointment ahead of the upcoming report. Lilly Q3 earnings preview Negative Sentiment: Institutional trimming adds selling pressure. Polen Capital reduced its position in Lilly during the third quarter, although it reportedly maintained confidence in the company’s outlook. Polen Capital trims Lilly position Analyst Ratings Changes A number of research analysts have issued reports on the company. Weiss Ratings upgraded Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, October 15th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $1,500.00 price target on shares of Eli Lilly and Company in a research note on Monday, October 12th. Wells Fargo & Company raised their price objective on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. The Goldman Sachs Group restated a “buy” rating and set a $1,413.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday. Finally, TD Cowen reaffirmed a “buy” rating and issued a $1,250.00 target price on shares of Eli Lilly and Company in a report on Tuesday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $1,317.93. Get Our Latest Stock Report on Eli Lilly and Company

LLY stock opened at $1,275.50 on Friday. The stock’s 50 day simple moving average is $1,186.64 and its 200 day simple moving average is $1,120.24. The company has a market cap of $1.20 trillion, a P/E ratio of 42.80, a price-to-earnings-growth ratio of 1.74 and a beta of 0.46. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a fifty-two week low of $809.63 and a fifty-two week high of $1,321.21.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company had revenue of $22.97 billion during the quarter, compared to the consensus estimate of $20.82 billion. During the same period in the previous year, the firm posted $6.31 earnings per share. The firm’s revenue for the quarter was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts expect that Eli Lilly and Company will post 33.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the completion of the transaction, the executive vice president owned 11,875 shares in the company, valued at approximately $14,131,250. The trade was a 29.63% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares in the company, valued at $63,628,139.70. This represents a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 13,500 shares of company stock worth $15,958,170. Insiders own 0.14% of the company’s stock.

Eli Lilly and Company Profile (Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.

Featured Articles Five stocks we like better than Eli Lilly and Company Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Halter Ferguson Financial Inc. trimmed its position in Eli Lilly and Company (NYSE: LLY) by 90.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 814 shares of the company's stock after selling 7,473 shares during the

Eli Lilly chair and CEO Dave Ricks discusses the company's expansion and 150th year in business on ‘Claman's Power Players.' #fox #foxbusiness #media #breakingnews #us #usa #new #news #breaking #clamanspowerplayers #lizclaman #claman #elililly #davericks #ricks #weightloss #weightlossdrugs #obesity #obesitytreatment #glp1 #pharmaceuticals #pharma #pharmaceuticalindustry #healthcare #healthcareinnovation #drugdevelopment #artificialintelligence #ai #aitechnology #biotech #biotechnology #medicalresearch #medicine #business #businessnews #innovation #technology #drugdiscovery #healthtech #ceo #corporateexpansion

Investors await next Thursday's results as strong prescription volumes face lower realized prices. -

Summary

Full-year revenue guidance stands at $85 billion–$87 billion.

Diabetes and obesity-drug maker Eli Lilly LLY traded at $1,284.51, down approximately 1.70% at 10.09am EST, on October 23. With earnings due next Thursday, according to Reuters' earnings preview, the key question is whether surging demand can keep overpowering weaker pricing.

Lilly's second-quarter results put that tension in numbers: revenue climbed 48% to $23 billion as volume increased 60%, while realized prices declined 13%. Mounjaro and Zepbound generated roughly $14.9 billion combined. Management raised its full-year revenue outlook to $85 billion–$87 billion, setting a demanding benchmark for the next report.

The valuation picture shows shares 19.01% below the GF Value estimate of roughly $1,590, suggesting potential upside against that model rather than a guaranteed bargain. Demand is powerful. Turning it into profitable growth remains the test. Investors should watch realized pricing, gross margin and manufacturing progress to judge whether higher prescription volumes are delivering enough earnings power.

Disclosures
I/we have no positions in any stocks mentioned, and have no plans to buy any new positions in the stocks mentioned within the next 72 hours.

Click for the complete disclosure

Eli Lilly reaches a record high ahead of earnings, strengthening its bullish trend as technical signals point toward potential upside targets between $1,384 and $1,406.

First Lilly site to produce both active pharmaceutical ingredients and finished medicines in a fully integrated facility Site will create 650 high-wage jobs INDIANAPOLIS, Oct. 22, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) broke ground today on a new $5 billion manufacturing facility just west of Richmond, Virginia, in Goochland County, one of 10 new U.S. manufacturing sites announced since 2020 and one of five among them that will produce active pharmaceutical ingredients (API). As part of the company's more than $50 billion push to expand medicine production in the U.S., the Richmond site will be Lilly's first to produce both API and finished medicines in a fully integrated facility, with dedicated API capacity for bioconjugate and large-molecule medicines.

Bank Pictet & Cie Europe AG lowered its stake in Eli Lilly and Company (NYSE:LLY – Free Report) by 16.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 37,664 shares of the company’s stock after selling 7,313 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Eli Lilly and Company were worth $43,580,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. raised its holdings in shares of Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock worth $81,009,981,000 after acquiring an additional 1,046,558 shares during the period. State Street Corp lifted its position in Eli Lilly and Company by 1.7% in the 2nd quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after acquiring an additional 605,752 shares in the last quarter. Bank of America Corp DE acquired a new position in Eli Lilly and Company in the 2nd quarter worth $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Eli Lilly and Company by 1.9% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock worth $8,647,153,000 after purchasing an additional 137,364 shares during the period. Finally, Jennison Associates LLC increased its holdings in Eli Lilly and Company by 7.9% during the 2nd quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock worth $6,550,587,000 after purchasing an additional 400,538 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insider Activity at Eli Lilly and Company In related news, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares in the company, valued at approximately $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 13,500 shares of company stock valued at $15,958,170. 0.14% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades Several analysts have issued reports on LLY shares. BMO Capital Markets reissued an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, October 1st. Wall Street Zen cut Eli Lilly and Company from a “buy” rating to a “hold” rating in a research report on Saturday, October 17th. Bank of America upped their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Morgan Stanley increased their price objective on Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the stock an “overweight” rating in a report on Wednesday, October 7th. Finally, Weiss Ratings raised Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a research report on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $1,317.93. Get Our Latest Analysis on Eli Lilly and Company

Key Eli Lilly and Company News Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Higher analyst target and expected earnings strength: Goldman Sachs raised its price target to $1,413 from $1,371 while maintaining a Buy rating. The firm reportedly expects Eli Lilly to beat third-quarter estimates and raise its outlook, supported by international Mounjaro growth and Zepbound volume gains. Goldman Sachs raises Eli Lilly price target Positive Sentiment: International manufacturing expansion: Eli Lilly signed Abu Dhabi agreements involving local packaging and advanced pharmaceutical contract manufacturing for weight-loss medicines. The company also entered a drug-delivery partnership with China’s Metis TechBio valued at up to $1.1 billion, potentially strengthening supply capacity and product-delivery capabilities. Eli Lilly Abu Dhabi packaging deal Positive Sentiment: Pipeline expansion: One-year Phase 3 SHINE-2 data showed Omvoh sustained clinical-remission benefits in children with ulcerative colitis, including patients who had previously failed biologic treatments. Regulatory approval could expand Lilly’s inflammatory bowel disease franchise. Pediatric ulcerative colitis data Neutral Sentiment: Strong growth, but pricing is a key upcoming issue: Second-quarter revenue increased 48% to approximately $23 billion as medicine volume rose 60%, while realized price per unit declined 13%. Investors will focus on whether continued demand and volume growth can offset pricing pressure when third-quarter results are released on October 29. Eli Lilly volume and pricing analysis Negative Sentiment: Competition and valuation risks: Novo Nordisk’s CagriSema produced 25% weight loss in women, reinforcing competitive pressure in the obesity-treatment market. After a substantial rally and record valuation, investors may also be taking profits or demanding stronger evidence that Lilly’s growth can justify its premium multiple. Novo Nordisk CagriSema results Eli Lilly and Company Stock Performance Shares of NYSE LLY opened at $1,271.89 on Thursday. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. The stock has a 50 day moving average price of $1,182.84 and a 200 day moving average price of $1,116.53. The stock has a market capitalization of $1.20 trillion, a PE ratio of 42.68, a price-to-earnings-growth ratio of 1.71 and a beta of 0.46. Eli Lilly and Company has a 52 week low of $793.82 and a 52 week high of $1,311.75.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%. The firm had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same quarter in the previous year, the firm earned $6.31 EPS. The business’s quarterly revenue was up 47.7% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Analysts predict that Eli Lilly and Company will post 33.56 earnings per share for the current fiscal year.

(Free Report)

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.

Read More Five stocks we like better than Eli Lilly and Company GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall? Intercepting Growth: Karman Secures $218M Lockheed Martin Deal Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Business is booming, and the pipeline of new treatments is robust.

*Stock prices used were the afternoon prices of Oct. 18, 2026. The video was published on Oct. 20, 2026.

Parkev Tatevosian, CFA has positions in Eli Lilly. The Motley Fool has positions in and recommends Eli Lilly. The Motley Fool has a disclosure policy. Parkev Tatevosian is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through his link, he will earn some extra money that supports his channel. His opinions remain his own and are unaffected by The Motley Fool.

As of 11:36 AM ET, the Dow Jones Industrial Average (^DJI +1.03%) is up 0.91% to 52,437 as blue-chips outperform, while the S&P 500 (^GSPC +0.40%) has climbed 0.31% to 7,715 and the Nasdaq Composite (^IXIC +0.20%) is up 0.08% to 26,460.

Index

S&P 500 IndexToday's Change

(

0.40

%)

+

30.97

Index Level

7,721.70

Gold is trading down 0.20% to $4,131.70, and the 10-Year Treasury yield fell 3 basis points to 5.11%. The utilities and healthcare sectors led the gainers while communication stocks fell.

Today's biggest movesEli Lilly climbed 5% this morning on metabolic drug pipeline advancements, while 3M surged following an earnings beat and data-center deal with Amazon.com. Conversely, General Motors tumbled over 6% as rising cost pressures overshadowed strong truck sales, and Steel Dynamics traded lower following an earnings miss.

What this means for investorsBlue chip stocks outperformed this morning as the Dow gained 600 points following a retreat in oil prices amid new hopes of diplomatic progress in the Middle East. Data showing a plunge in pending home sales for September put additional pressure on homebuilders and real estate stocks.

Tech stocks remain volatile, though chipmakers edged higher today, potentially driven by dip buying. News that South Korean data center provider, Elice Inc., plummeted more than 30% on its first day of trading on the Kosdaq shows that investors remain cautious on the artificial intelligence (AI) trade.

SpaceX earnings, due after the bell today, along with Meta Platforms tomorrow, will give more insight into the sustainability of heavy AI spending. For investors, a long-term focus on maintaining a diversified portfolio of companies with strong fundamentals remains crucial.

Emma Newbery has positions in Amazon. The Motley Fool has positions in and recommends Amazon, Eli Lilly, Intel, Meta Platforms, and Micron Technology. The Motley Fool recommends 3M, General Motors, and Steel Dynamics. The Motley Fool has a disclosure policy.

In the latest trading session, Eli Lilly (LLY - Free Report) closed at $1,240.34, marking a -1.33% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 0.41% for the day. Elsewhere, the Dow lost 0.07%, while the tech-heavy Nasdaq added 1.11%.

The stock of drugmaker has risen by 9.03% in the past month, leading the Medical sector's gain of 1.97% and the S&P 500's gain of 1.46%.

The upcoming earnings release of Eli Lilly will be of great interest to investors. The company's earnings report is expected on October 29, 2026. It is anticipated that the company will report an EPS of $5.38, marking a 23.36% fall compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $22.11 billion, indicating a 25.59% growth compared to the corresponding quarter of the prior year.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $33.56 per share and a revenue of $88.94 billion, signifying shifts of +38.62% and +36.45%, respectively, from the last year.

Investors should also note any recent changes to analyst estimates for Eli Lilly. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 8.14% lower within the past month. Eli Lilly is currently sporting a Zacks Rank of #3 (Hold).

From a valuation perspective, Eli Lilly is currently exchanging hands at a Forward P/E ratio of 37.46. This signifies a premium in comparison to the average Forward P/E of 16.91 for its industry.

Also, we should mention that LLY has a PEG ratio of 1.67. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Large Cap Pharmaceuticals was holding an average PEG ratio of 2.01 at yesterday's closing price.

The Large Cap Pharmaceuticals industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 210, positioning it in the bottom 15% of all 250+ industries.

The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

You can find more information on all of these metrics, and much more, on Zacks.com.

Eli Lilly (LLY -0.68%) is expanding access at lower realized prices while its margins continue to improve. That unusual combination could become even more important as manufacturing costs fall, retatrutide approaches a potential 2027 filing, and investors weigh whether the company's valuation still leaves room for growth.

Stock prices used were the market prices of Sept. 26, 2026. The video was published on Oct. 17, 2026.

Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Eli Lilly. The Motley Fool has a disclosure policy. Rick Orford is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link, they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.

Hong Kong-listed Metis TechBio (7666.HK) said on Monday it has entered ​into a collaboration agreement with Eli ‌Lilly (LLY.N) worth up to $1.1 billion to research and develop tissue-specific drug delivery technologies.

The Chinese biotech will ​use its proprietary AI-driven drug-delivery platform ​to develop next-generation technologies aimed at ⁠improving how LNP-based drugs reach target tissues.

Metis ​will be eligible to receive an upfront ​payment in the low double-digit millions US dollars and up to about $1.1 billion in development, regulatory ​and commercial milestone payments.

It will also ​be eligible for tiered royalties at a single-digit percentage ‌of ⁠annual net sales of products that are developed due to the collaboration.

The Chinese biotech will use its proprietary AI-driven ionizable ​lipid discovery and ​optimisation ⁠platform to develop delivery technologies aimed at improving the targeting and ​biodistribution of LNP-based therapies.

Metis and ​Lilly ⁠aim to discover and optimise novel LNP architectures that could improve tissue specificity and ⁠therapeutic ​performance, with potential applications ​across multiple disease areas.

Warren Buffett has delivered warnings to Wall Street in recent years as the S&P 500 soared to new highs. In some cases, the warning came in the form of an increasing cash pile. For more than a dozen quarters, Buffett, at the helm of Berkshire Hathaway, was a net seller of stocks.

Today, Buffett is in retirement, so he no longer holds the role of Berkshire Hathaway chief executive officer. But he is the chairman emeritus and still participates in investment discussions. And he is also clearly present at shareholder meetings and speaks openly about investing, as he's done throughout his career. During the latest meeting, in May, he delivered his bluntest warning yet.

"We've never had people in a more gambling mood than now," he told CNBC during an interview. Buffett referred to individuals rushing into short-term options and betting on markets rather than focusing on long-term investing. This behavior is risky for those taking part in it, and it may represent a risk for the market as well, leading to an eventual drop.

Now here are two bits of good news. First, the S&P 500 and quality stocks have always recovered after market turmoil. And second, certain stocks are built to survive troubled times. The pharma and biotech industries are a great place to look for such companies since patients always need their treatments, regardless of the economic backdrop. Here are three top stocks to consider.

Image source: Getty Images.

1. Vertex Pharmaceuticals
Vertex Pharmaceuticals (VRTX -1.77%) is the global leader in cystic fibrosis (CF) treatment, and this business has helped the company generate billion-dollar revenue over time. The biotech's strong intellectual property translates into leadership here through at least the late 2030s. Vertex makes CFTR modulators, or treatments designed to correct the malfunctioning protein that causes symptoms of the disease.

VRTX Vertex Pharmaceuticals$499.74-$9.01 (-1.77%)

NASDAQ · As of 4:00 PM ET 10/16/26

In recent years, Vertex has expanded into other treatment areas, winning approval for a gene editing therapy for blood disorders and a non-opioid drug for pain. And Vertex continues to expand, with the most recent effort being the purchase of Crinetics Pharmaceuticals, a player in the endocrine disorders space. The deal brings a commercialized product and pipeline candidates, and it's expected to add to non-GAAP operating income in 2029.

The combination of Vertex's leading CF business and these recent expansions offers investors stability and potential for growth in any economic environment.

2. Eli Lilly
Eli Lilly (LLY +0.43%) dominates one of the highest-growth pharmaceutical areas around, and that's the weight loss drug market. The company sells tirzepatide, commercialized as Mounjaro for type 2 diabetes and as Zepbound for weight loss. And each of these products is bringing in blockbuster revenue.

LLY Eli Lilly$1,257.03+$5.42 (+0.43%)

NYSE · As of 4:00 PM ET 10/16/26

In the recent quarter, they generated more than $14 billion on total revenue of $23 billion. We could see additional growth in the coming years as Lilly recently launched its first weight loss pill, Foundayo, and is bringing other promising weight loss candidates through the pipeline.

Meanwhile, Lilly also sells a broad range of other drugs across treatment areas, so it doesn't depend uniquely on the weight loss market for growth. Still, this market, on track to reach nearly $100 billion by then end of the decade, very likely will represent a major growth driver for Lilly for years to come.

3. AbbVie
AbbVie (ABBV +0.71%) is the maker of one of the world's best-selling drugs over time, the immunology drug Humira. The pharma giant lost exclusivity on Humira in recent years and has proven its ability to beat that challenge, thanks to the strength of the rest of its immunology portfolio.

Its newer immunology drugs, Rinvoq and Skyrizi, are growing in the double digits and bringing in blockbuster revenue. In the latest quarter, they delivered 24% growth each to revenue of $2.5 billion and $5.5 billion, respectively.

ABBV AbbVie$285.42+$2.02 (+0.71%)

NYSE · As of 4:00 PM ET 10/16/26

AbbVie sells other leading drugs across treatment areas, from Botox in the aesthetics portfolio to Vraylar for depression in the neuroscience portfolio.

Investors will also like AbbVie for its status as a Dividend King, having lifted its payments for more than 50 consecutive years. So with AbbVie, investors gain access to reliable revenue and passive income, making it a fantastic stock to own during any market environment.

First Phase 1 data for sofetabart mipitecan, Lilly's investigational FRα-targeting ADC, in platinum-sensitive ovarian cancer to be featured in a rapid oral presentation

Updated first-line data for olomorasib, an investigational therapy targeting KRAS G12C-mutant NSCLC, to be featured in a rapid oral presentation

Updated Phase 3 data for selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitor-naïve, RET-mutant MTC to be shared in a proffered paper

, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that new data from across its oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 23–27 in Madrid, Spain. Highlights include new Phase 1 data in platinum-sensitive ovarian cancer (PSOC) for sofetabart mipitecan (Sofe-M), Lilly's investigational FRα-targeting antibody-drug conjugate (ADC), in combination with bevacizumab, along with updated findings for olomorasib, Retevmo (selpercatinib), and Verzenio (abemaciclib) in lung, thyroid, and breast cancers, respectively. 

Key Presentation Highlights:

Sofetabart mipitecan (Sofe-M; FRα-targeting ADC): A rapid oral presentation on first Phase 1 data for sofetabart mipitecan plus bevacizumab in patients with PSOC. These data support the ongoing Phase 3 clinical trial of Sofe-M in PSOC.

Olomorasib (investigational KRAS G12C inhibitor):
A rapid oral presentation on an updated integrated analysis from the Phase 1/2 LOXO-RAS-20001 trial and the safety lead-in portion of the Phase 3 SUNRAY-01 trial, assessing olomorasib in combination with chemoimmunotherapy (pembrolizumab, pemetrexed, and platinum) as potential first-line treatments for patients with advanced/metastatic KRAS G12C-mutant non-small cell lung cancer (NSCLC). These data support the ongoing Phase 3 clinical trial of olomorasib in first-line KRAS G12C-mutant lung cancer.

Retevmo (selpercatinib; RET kinase inhibitor): A proffered paper presentation on updated results from the Phase 3 LIBRETTO-531 study of selpercatinib versus cabozantinib or vandetanib (C/V) in advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer (MTC). These data have supported global approvals of Retevmo in this treatment setting.

Verzenio (abemaciclib; CDK4/6 inhibitor): A rapid oral presentation on overall survival data from the Phase 3 postMONARCH trial of abemaciclib plus fulvestrant in HR-positive, HER2-negative advanced breast cancer following progression on a prior CDK4/6 inhibitor and endocrine therapy. These data support the abemaciclib plus imlunestrant results in the EMBER-3 trial and add to the evidence-based practice of switching endocrine therapy and CDK4/6 inhibitor at progression in metastatic breast cancer.

"Lilly's presentations at ESMO reflect both the breadth of our oncology portfolio and the focus behind it: following compelling science wherever it has the potential to change care," said Jacob Van Naarden, executive vice president and president of Lilly Oncology. "We're especially encouraged by the data we're sharing for sofetabart mipitecan in platinum-sensitive ovarian cancer, which build on what we've seen with this medicine in platinum-resistant disease and mark a critical step forward as we advance the ongoing Phase 3 FRAmework-01 study across both settings. Our updated first-line data for olomorasib in KRAS G12C-mutant lung cancer are very promising, with clinical activity and a safety profile consistent with earlier findings, which reinforce the importance of targeted therapy for patients from the outset of their treatment journey. Alongside new data in thyroid and breast cancers, these presentations represent meaningful momentum toward improving care for people with cancer."

A full list of abstract titles and viewing details are listed below:

Abstract Title

Author

Presentation
Type/#

Session Title

Session Date/Time

(CET)

Sofe-M (sofetabart mipitecan; investigational ADC targeting FRα):

Model-informed Phase 3 dose
selection for antibody-drug conjugate
(ADC) sofetabart mipitecan (Sofe-M):
First prospective application of a
clinical utility index (CUI) 

Jean-
Sebastien
Frenel

Poster
#1016P

Poster display
session

Friday, October 23

15:15-16:00

Efficacy and safety
of sofetabart mipitecan (Sofe-M), a
folate receptor alpha (FRα) targeting
antibody drug conjugate (ADC), plus
bevacizumab in recurrent platinum
sensitive ovarian cancer (PSOC) 

Chrisann Kyi

Rapid oral
#1246RO

Rapid oral 2:
Gynecological
cancers

Saturday, October 24

8:30-10:00

Sofetabart mipitecan (Sofe-M) in
patients ≥65 y with platinum-resistant
and -sensitive ovarian cancer
(PROC/PSOC) from the first-in-human
phase 1 study 

Ana Oaknin

Poster
#1288P

Poster display
session

Monday, October 26

12:00-12:45

Olomorasib (investigational KRAS G12C inhibitor)

First-line (1L) olomorasib +
chemoimmunotherapy (Chemo-IO) in
KRAS G12C-mutant NSCLC: Updated
results from the LOXO-RAS-20001 and
SUNRAY-01 trials 

Marcelo V.
Negrao

Rapid oral
#2652RO

Rapid oral 2:
NSCLC, metastatic

Sunday,

October 25

8:30-10:00

First-line (1L) olomorasib +
pembrolizumab in KRAS G12C-mutant
NSCLC: Updated results from LOXO-
RAS-20001 and SUNRAY-01 

Melissa L.
Johnson

Poster
#2683P

Poster display
session

Monday, October 26

12:00-12:45

Retevmo (selpercatinib; RET kinase inhibitor)

Updated results of randomized Phase
3 study of selpercatinib vs
cabozantinib or vandetanib (C/V) in
advanced, kinase inhibitor-naïve, RET-
mutant medullary thyroid cancer
(MTC) 

Jaume
Capdevila

Proffered paper
#4208O

Proffered paper:
NETs and
endocrine tumors

Monday, October 26

10:15-11:45

Verzenio (abemaciclib; CDK4/6 inhibitor)

Association of p27 V109G SNP zygosity
with outcomes
and abemaciclib treatment effect in
HR+, HER2– high-risk early breast
cancer: results from monarchE 

Miguel
Quintela-
Fandino

Poster
#4498P

Poster display
session

Friday, October 23

15:15-16:00

Overall survival from the Phase
3 postMONARCH trial of abemaciclib +
fulvestrant vs placebo + fulvestrant for
HR+, HER2– advanced breast cancer
following progression on a prior
CDK4/6 inhibitor + endocrine therapy 

Kevin Kalinsky

Rapid oral
#1RO

Rapid oral 1:
Breast cancer,
advanced stage

Saturday, October 24

10:15-11:45

Three-month persistence and
adherence to adjuvant abemaciclib in
high-risk HR+, HER2– early breast
cancer: real world data from ABSIDE-S 

Isabel Blancas
López-Barajas

ePoster
#1933eP

ePoster session

Friday, October 23

8:00

Treatment persistence and clinical
characteristics in patients with HR+,
HER2–, high-risk early breast cancer
(EBC) treated with abemaciclib: A
multi-country real-world study  

Hitomi Sakai

ePoster
#615eP

ePoster session

Friday, October 23

8:00

For more information on Lilly's oncology pipeline, click here.

About Sofetabart Mipitecan
Sofetabart mipitecan (Sofe-M; LY4170156) is composed of an Fc-silent, folate receptor alpha (FRα) specific humanized monoclonal antibody linked to exatecan, a topoisomerase I inhibitor, via a proprietary cleavable polysarcosine linker (PSARlink). Sofe-M was designed to target FRα across all expression levels with an improved therapeutic index. FRα is a cell-surface glycoprotein encoded by the gene FOLR1 that binds to the essential nutrients folic acid and reduced folates, bringing them into cells to facilitate cell division and growth.1,2 FRα is overexpressed in many solid tumors such as ovarian and endometrial cancers.1,3,4 Sofe-M has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for platinum-resistant ovarian cancer (PROC) and is currently being evaluated in the Phase 3 FRAmework-01 trial. The study is being conducted in partnership with the European Network for Gynaecological Oncological Trial groups (ENGOT – lead groups GINECO/NOGGO e.V.), the GOG Foundation (GOG), and the Asia-Pacific Gynecologic Oncology Trials Group (APGOT).

About Olomorasib
Olomorasib (LY3537982) is an investigational, oral, potent, and highly selective second-generation inhibitor of the KRAS G12C protein. KRAS is the most common oncogene across all tumor types, and KRAS G12C mutations occur in 13% of patients with non-small cell lung cancer (NSCLC), and 1–3% of patients with other solid tumors.5 Olomorasib is a highly potent covalent inhibitor with potential for greater than 90% target occupancy, which may allow for safer combinations with less toxicity.6

Olomorasib is currently being studied in KRAS G12C-mutant cancers in combination with pembrolizumab with or without chemotherapy for first-line treatment of advanced NSCLC, in combination with immunotherapy for the treatment of resected and unresectable NSCLC, and as monotherapy and in combinations in other advanced solid tumors (NCT06119581, NCT06890598, and NCT04956640).

About Retevmo
Retevmo (selpercatinib, formerly known as LOXO-292) (pronounced reh-TEHV-moh) is a highly selective and potent RET kinase inhibitor with central nervous system (CNS) activity. Retevmo may affect both tumor cells and healthy cells, which can result in side effects. RET-driver alterations are predominantly mutually exclusive from other oncogenic drivers. Retevmo is a U.S. FDA-approved oral prescription medicine, 120 mg or 160 mg dependent on weight (<50 kg or ≥50 kg, respectively), taken twice daily until disease progression or unacceptable toxicity.7

INDICATIONS FOR RETEVMO (selpercatinib)
RETEVMO is a kinase inhibitor indicated for the treatment of:

Adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy IMPORTANT SAFETY INFORMATION FOR RETEVMO (selpercatinib)

Hepatotoxicity: Serious hepatic adverse reactions occurred in 4.6% of patients treated with Retevmo. Increased aspartate aminotransferase (AST) occurred in 62% of patients, including Grade 3 or 4 events in 11% and increased alanine aminotransferase (ALT) occurred in 58% of patients, including Grade 3 or 4 events in 13%. Monitor ALT and AST prior to initiating Retevmo, every 2 weeks during the first 3 months, then monthly thereafter and as clinically indicated. Withhold, reduce dose, or permanently discontinue Retevmo based on severity.

Severe, life-threatening, and fatal interstitial lung disease (ILD)/pneumonitis can occur in patients treated with Retevmo. ILD/pneumonitis occurred in 3% of patients who received Retevmo, including 0.3% with Grade 3 or 4 events, and 0.2% with fatal reactions. Monitor for pulmonary symptoms indicative of ILD/pneumonitis. Withhold Retevmo and promptly investigate for ILD in any patient who presents with acute or worsening of respiratory symptoms which may be indicative of ILD (e.g., dyspnea, cough, and fever). Withhold, reduce dose, or permanently discontinue Retevmo based on severity of confirmed ILD.

Hypertension occurred in 43% of patients, including Grade 3 hypertension in 20% and Grade 4 in one (0.1%) patient. Overall, 6.4% had their dose interrupted, 1.5% had their dose reduced, and 0.2% discontinued Retevmo for hypertension. Treatment-emergent hypertension was most commonly managed with anti-hypertension medications. Do not initiate Retevmo in patients with uncontrolled hypertension. Optimize blood pressure prior to initiating Retevmo. Monitor blood pressure after 1 week, at least monthly thereafter, and as clinically indicated. Initiate or adjust anti-hypertensive therapy as appropriate. Withhold, reduce dose, or permanently discontinue Retevmo based on severity.

Retevmo can cause concentration-dependent QT interval prolongation. An increase in QTcF interval to >500 ms was measured in 8% of patients and an increase in the QTcF interval of at least 60 ms over baseline was measured in 22% of patients. Retevmo has not been studied in patients with clinically significant active cardiovascular disease or recent myocardial infarction. Monitor patients who are at significant risk of developing QTc prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, and severe or uncontrolled heart failure. Assess QT interval, electrolytes, and thyroid-stimulating hormone (TSH) at baseline and periodically during treatment, adjusting frequency based upon risk factors including diarrhea.

Correct hypokalemia, hypomagnesemia, and hypocalcemia prior to initiating Retevmo and during treatment. Monitor the QT interval more frequently when Retevmo is concomitantly administered with strong and moderate CYP3A inhibitors or drugs known to prolong QTc interval. Withhold and dose reduce or permanently discontinue Retevmo based on the severity.

Serious, including fatal, hemorrhagic events can occur with Retevmo. Grade ≥3 hemorrhagic events occurred in 4.3% of patients treated with Retevmo including 4 (0.5%) patients with fatal hemorrhagic events, including cerebral hemorrhage (n=2), tracheostomy site hemorrhage and hemoptysis (1 each). Permanently discontinue Retevmo in patients with severe or life-threatening hemorrhage.

Retevmo can cause hypersensitivity, including severe skin reactions such as Stevens-Johnson Syndrome. All grade hypersensitivity occurred in 6% of patients receiving Retevmo, including Grade 3 in 2%. The median time to onset was 1.9 weeks (range: 5 days to 6.5 years). Signs and symptoms of hypersensitivity included fever, rash and arthralgias or myalgias with concurrent decreased platelets or transaminitis. Stevens-Johnson Syndrome has been observed in the post-marketing setting. Discontinue Retevmo in patients with Stevens-Johnson Syndrome. If hypersensitivity occurs, withhold Retevmo and begin corticosteroids at a dose of 1 mg/kg prednisone (or equivalent). Upon resolution of the event, resume Retevmo at a reduced dose and increase the dose of Retevmo by 1 dose level each week as tolerated until reaching the dose taken prior to onset of hypersensitivity. Continue steroids until patient reaches target dose and then taper. Permanently discontinue Retevmo for recurrent hypersensitivity.

Tumor lysis syndrome (TLS) occurred in 0.9% of patients with medullary thyroid carcinoma and 0.3% of patients with non-small cell lung cancer receiving Retevmo. Patients may be at risk of TLS if they have rapidly growing tumors, a high tumor burden, renal dysfunction, or dehydration. Closely monitor patients at risk, consider appropriate prophylaxis including hydration, and treat as clinically indicated.

Impaired wound healing can occur in patients who receive drugs that inhibit the vascular endothelial growth factor (VEGF) signaling pathway. Therefore, Retevmo has the potential to adversely affect wound healing. Withhold Retevmo for at least 7 days prior to elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of Retevmo after resolution of wound healing complications has not been established.

Retevmo can cause hypothyroidism. Hypothyroidism occurred in 15% of patients treated with Retevmo; all reactions were Grade 1 or 2. Hypothyroidism occurred in 15% of patients (59/390) with thyroid cancer and 14% of patients (65/467) with other solid tumors including NSCLC. Monitor thyroid function before treatment with Retevmo and periodically during treatment. Treat with thyroid hormone replacement as clinically indicated. Withhold Retevmo until clinically stable or permanently discontinue Retevmo based on severity.

Based on data from animal reproduction studies and its mechanism of action, Retevmo can cause fetal harm when administered to a pregnant woman. Administration of selpercatinib to pregnant rats during organogenesis at maternal exposures that were approximately equal to those observed at the recommended human dose of 160 mg twice daily resulted in embryolethality and malformations. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with Retevmo and for 1 week after the last dose. There are no data on the presence of selpercatinib or its metabolites in human milk or on their effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed children, advise women not to breastfeed during treatment with Retevmo and for 1 week after the last dose.

Slipped capital femoral epiphysis/slipped upper femoral epiphysis in pediatric patients (SCFE/SUFE) occurred in 1 adolescent (2.8% of 36 patients) receiving Retevmo in LIBRETTO-121 and 1 adolescent patient (0.5% of 193 patients) receiving Retevmo in LIBRETTO-531. Monitor patients for symptoms indicative of SCFE/SUFE and treat as medically and surgically appropriate.

Severe adverse reactions (Grade 3-4) occurring in ≥20% of patients who received Retevmo in LIBRETTO-001 were hypertension (20%), diarrhea (6.2%), prolonged QT interval (5%), fatigue (4.7%), musculoskeletal pain (4.1%), dyspnea (4.1%), hemorrhage (3.9%), abdominal pain (3.5%), vomiting (2.9%), urinary tract infection (2.2%), nausea (1.9%), headache (1.8%), edema (1.3%), decreased appetite (0.9%), constipation (0.8%), rash (0.8%), and dizziness (0.5%).

Severe adverse reactions (Grade 3-4) occurring in ≥15% of patients who received Retevmo in LIBRETTO-121 were increased weight (11%), vomiting (8%), constipation (6%), diarrhea (2.8%), nausea (2.8%), upper respiratory tract infection (2.8%), and urinary tract infection (2.8%).

Severe adverse reactions (Grade 3-4) occurring in ≥15% of patients who received Retevmo or chemotherapy with or without pembrolizumab in LIBRETTO-431 were hypertension (20% vs 3.1%), electrocardiogram QT prolonged (9% vs 0%), fatigue (3.2% vs 5%), edema (2.5% vs 0%), rash (1.9% vs 1.0%), diarrhea (1.3% vs 2.0%), abdominal pain (0.6% vs 2.0%), pyrexia (0.6% vs 0%), COVID19 infection (0.6% vs 0%), constipation (0% vs 1.0%), nausea (0% vs 1.0%), vomiting (0% vs 1.0%), and decreased appetite (0% vs 2.0%).

Severe adverse reactions (Grade 3-4) occurring in ≥10% of patients who received Retevmo in LIBRETTO-531 were (Retevmo vs cabozantinib / vandetanib) hypertension (19% vs 18%), electrocardiogram QT prolonged (4.7% vs 2.1%), fatigue (4.1% vs 9%), diarrhea (3.1% vs 8%), rash (1.6% vs 4.1%), pyrexia (1.0% vs 0%), nausea (1.0% vs 5%), dry mouth (0.5% vs 1.0%), abdominal pain (0.5% vs 2.1%), stomatitis (0.5% vs 13%), headache (0.5% vs 0%), and decreased appetite (0.5% vs 5%).

Serious adverse reactions occurred in 58% of patients who received Retevmo in LIBRETTO-001. The most frequently reported serious adverse reactions (in ≥2% of patients) were pneumonia, hemorrhage, abdominal pain, dyspnea, pleural effusion, sepsis, musculoskeletal pain, hyponatremia, vomiting, diarrhea, and increased blood creatinine. Fatal adverse reactions occurred in 3% of patients in LIBRETTO-001; fatal adverse reactions included sepsis (n=6), respiratory failure (n=5), hemorrhage (n=4), pneumonia (n=4), cardiac arrest (n=3), pneumonitis (n=2), cardiac failure (n=2), sudden death (n=1), cerebral infarction (n=1), and dyspnea (n=1).

Serious adverse reactions occurred in 42% of patients who received Retevmo in LIBRETTO-121. Serious adverse reactions occurring in more than 1 patient were vomiting and fracture (2 patients each).

Serious adverse reactions occurred in 35% of patients who received Retevmo in LIBRETTO-431. The most frequently reported serious adverse reactions (≥2% of patients) were pleural effusion and abnormal hepatic function. Fatal adverse reactions occurred in 4.4% of patients who received Retevmo in LIBRETTO-431; fatal adverse reactions included myocardial infarction (n=2), respiratory failure (n=2), cardiac arrest, malnutrition, and sudden death (n=1 each).

Serious adverse reactions occurred in 22% of patients who received Retevmo in LIBRETTO-531. The most frequent serious adverse reactions were pneumonia and pyrexia (n=3 each), and hypertension and urinary tract infection (n=2 each). Fatal adverse reactions occurred in 2.1% of patients who received Retevmo in LIBRETTO-531; fatal adverse reactions included COVID19, diabetic ketoacidosis, multiple organ dysfunction syndrome, and sudden death (n=1 each).

Common adverse reactions (all grades) occurring in ≥20% of patients who received Retevmo in LIBRETTO-001 were musculoskeletal pain (59%), edema (53%), diarrhea (52%), fatigue (49%), dry mouth (44%), hypertension (43%), abdominal pain (39%), rash (38%), nausea (36%), constipation (35%), cough (30%), headache (30%), vomiting (29%), dyspnea (28%), hemorrhage (26%), decreased appetite (23%), dizziness (22%), prolonged QT interval (21%), and urinary tract infection (20%).

Common adverse reactions (all grades) occurring in ≥15% of patients who received Retevmo in LIBRETTO-121 were musculoskeletal pain (58%), diarrhea (47%), nausea (42%), hemorrhage (39%), pyrexia (39%), abdominal pain (36%), headache (33%), vomiting (31%), fatigue (31%), cough (31%), rash (28%), coronavirus infection (28%), upper respiratory tract infection (28%), edema (25%), constipation (22%), oropharyngeal pain (22%), hypothyroidism (22%), urinary tract infection (19%), and increased weight (19%).

Common adverse reactions (all grades) occurring in ≥15% of patients who received Retevmo or chemotherapy with or without pembrolizumab in LIBRETTO-431 were hypertension (48% vs 7%), diarrhea (44% vs 24%), edema (41% vs 28%), dry mouth (39% vs 6%), rash (33% vs 30%), fatigue (32% vs 50%), abdominal pain (25% vs 19%), musculoskeletal pain (25% vs 28%), constipation (22% vs 40%), electrocardiogram QT prolonged (20% vs 1.0%), COVID19 infection (19% vs 18%), stomatitis (18% vs 16%), decreased appetite (17% vs 34%), nausea (13% vs 44%), vomiting (13% vs 23%), and pyrexia (13% vs 23%).

Common adverse reactions (all grades) occurring in ≥10% of patients who received Retevmo in LIBRETTO-531 (Retevmo vs cabozantinib / vandetanib) were hypertension (43% vs 41%), edema (33% vs 5%), dry mouth (32% vs 10%), fatigue (28% vs 47%), diarrhea (26% vs 61%), headache (23% vs 21%), rash (19% vs 27%), abdominal pain (18% vs 21%), constipation (16% vs 12%), erectile dysfunction (16% vs 0%), stomatitis (14% vs 42%), electrocardiogram QT prolonged (14% vs 13%), pyrexia (12% vs 2.1%), decreased appetite (12% vs 28%), hypothyroidism (11% vs 21%), and nausea (10% vs 32%).

Laboratory abnormalities (all grades ≥20%; Grade 3-4) worsening from baseline in patients who received Retevmo in LIBRETTO-001, were increased AST (62%; 11%), decreased calcium (61%; 7%), decreased albumin (61%; 3.6%), increased ALT (58%; 13%), increased glucose (56%; 4.0%), decreased lymphocytes (56%; 22%), increased creatinine (51%; 3.6%), decreased sodium (49%; 13%), increased alkaline phosphatase (43%; 4.4%), decreased platelets (41%; 4.0%), increased potassium (39%; 3.5%), decreased glucose (39%; 1.5%), increased total cholesterol (37%; 1.7%), decreased magnesium (37%; 0.7%), decreased hemoglobin (36%; 4.1%), increased bilirubin (32%; 2.9%), decreased neutrophils (27%; 3.8%), and decreased phosphate (25%; 5%).

Laboratory abnormalities (all grades ≥15%; Grade 3-4) worsening from baseline in patients who received Retevmo in LIBRETTO-121 were decreased calcium (61%; 11%), increased ALT (58%; 8%), decreased albumin (53%; 0%), increased alkaline phosphatase (50%; 0%), increased AST (50%; 2.8%), increased bilirubin (31%; 2.8%), increased cholesterol (28%, 0%), decreased magnesium (28%; 6%), increased potassium (28%; 2.8%), increased creatinine (19%, 2.8%), decreased potassium (19%, 6%), decreased sodium (17%, 0%), decreased neutrophils (40%; 8%), decreased hemoglobin (36%; 11%), increased hemoglobin (33%, 2.8%), decreased platelets (28%; 2.8%), and decreased lymphocytes (28%; 14%).

Laboratory abnormalities (all grades ≥20%; Grade 3-4) worsening from baseline in patients who received Retevmo or chemotherapy with or without pembrolizumab in LIBRETTO-431 were increased ALT (81%; 21% vs 63%; 4.1%), increased AST (77%; 10% vs 46%; 0%), decreased calcium (53%; 1.9% vs 24%; 1.0%), decreased platelets (53%; 3.2% vs 39%; 5%), decreased lymphocytes (53%; 8% vs 64%; 15%), decreased neutrophils (53%; 2.0% vs 58%; 11%), increased bilirubin (52%; 1.3% vs 9%; 0%), increased alkaline phosphatase (35%; 1.3% vs 22%; 0%), decreased sodium (31%; 3.2% vs 41%; 2.1%), decreased albumin (25%; 0% vs 5%; 0%), increased blood creatinine (23%; 0% vs 21%; 0%), decreased hemoglobin (21%; 0% vs 91%; 5%), decreased potassium (17%; 1.3% vs 15%; 1.0%), and decreased magnesium (16%; 0.6% vs 8%; 0%).

Laboratory abnormalities (all grades ≥5%; Grade 3-4) worsening from baseline in patients who received Retevmo in LIBRETTO-531 (Retevmo vs cabozantinib / vandetanib) were decreased calcium (55%; 5% vs 62%; 11%), increased ALT (53%; 16% vs 72%; 7%), increased AST (47%; 5% vs 68%; 3.2%), decreased lymphocytes (41%; 18% vs 36%; 13%), increased alkaline phosphatase (37%; 6% vs 28%, 5%), increased bilirubin (32%; 1.1% vs 30%; 3.2%), decreased neutrophils (33%; 14% vs 42%; 19%), decreased platelets (28%; 1.1% vs 34%; 1.1%), increased creatinine (27%; 6% vs 16%; 8%), decreased sodium (20%; 3.2% vs 16%; 0%), decreased hemoglobin (18%; 2.1% vs 23%; 2.1%), decreased albumin (11%; 1.1% vs 7%; 0%), decreased magnesium (9%; 3.3% vs 26%; 9%), and decreased potassium (8%; 0% vs 22%; 4.4%).

Concomitant use of acid-reducing agents decreases selpercatinib plasma concentrations which may reduce Retevmo anti-tumor activity. Avoid concomitant use of proton-pump inhibitors (PPIs), histamine-2 (H2) receptor antagonists, and locally acting antacids with Retevmo. If coadministration cannot be avoided, take Retevmo with food (with a PPI) or modify its administration time (with a H2 receptor antagonist or a locally acting antacid).

Concomitant use of strong and moderate CYP3A inhibitors increases selpercatinib plasma concentrations which may increase the risk of Retevmo adverse reactions including QTc interval prolongation. Avoid concomitant use of strong and moderate CYP3A inhibitors with Retevmo. If concomitant use of a strong or moderate CYP3A inhibitor cannot be avoided, reduce the Retevmo dosage as recommended and monitor the QT interval with ECGs more frequently.

Concomitant use of strong and moderate CYP3A inducers decreases selpercatinib plasma concentrations which may reduce Retevmo anti-tumor activity. Avoid coadministration of Retevmo with strong and moderate CYP3A inducers.

Concomitant use of Retevmo with CYP2C8 and CYP3A substrates increases their plasma concentrations which may increase the risk of adverse reactions related to these substrates. Avoid coadministration of Retevmo with CYP2C8 and CYP3A substrates where minimal concentration changes may lead to increased adverse reactions. If coadministration cannot be avoided, follow recommendations for CYP2C8 and CYP3A substrates provided in their approved product labeling.

Retevmo is a P-glycoprotein (P-gp) and BCRP inhibitor. Concomitant use of Retevmo with P-gp or BCRP substrates increases their plasma concentrations, which may increase the risk of adverse reactions related to these substrates. Avoid coadministration of Retevmo with P-gp or BCRP substrates where minimal concentration changes may lead to increased adverse reactions. If coadministration cannot be avoided, follow recommendations for P-gp and BCRP substrates provided in their approved product labeling.

The safety and effectiveness of Retevmo have not been established in pediatric patients less than 2 years of age. The safety and effectiveness of Retevmo have been established in pediatric patients aged 2 years and older for the treatment of advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation who require systemic therapy, advanced or metastatic thyroid cancer with a RET gene fusion who require systemic therapy and are radioactive iodine-refractory (if radioactive iodine is appropriate), and locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.

Monitor open growth plates in pediatric patients. Consider interrupting or discontinuing Retevmo if abnormalities occur.

No dosage modification is recommended for patients with mild to severe renal impairment (estimated Glomerular Filtration Rate [eGFR] ≥15 to 89 mL/min, estimated by Modification of Diet in Renal Disease [MDRD] equation). A recommended dosage has not been established for patients with end-stage renal disease.

Reduce the dose when administering Retevmo to patients with severe hepatic impairment (total bilirubin greater than 3 to 10 times upper limit of normal [ULN] and any AST). No dosage modification is recommended for patients with mild or moderate hepatic impairment. Monitor for Retevmo-related adverse reactions in patients with hepatic impairment.

Retevmo (selpercatinib) is available as 40 mg and 80 mg capsules, and 40 mg, 80 mg, 120 mg, and 160 mg tablets.

SE HCP ISI All_JUL2026

Please see full Prescribing Information and Instructions for Use for Retevmo.

About Verzenio (abemaciclib)
Verzenio (abemaciclib) is approved to treat people with certain HR+, HER2– breast cancers in the adjuvant and advanced or metastatic settings. Verzenio is an oral tablet taken twice daily and available in strengths of 50 mg, 100 mg, 150 mg, and 200 mg. Discovered and developed by Lilly researchers, Verzenio was first approved in 2017 and is authorized for use in more than 90 countries around the world. For full details on indicated uses of Verzenio in HR+, HER2– breast cancer, please see full Prescribing Information, available at www.Verzenio.com.

INDICATIONS FOR VERZENIO 

Verzenio (abemaciclib) is a kinase inhibitor indicated8,9:

in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer. in combination with fulvestrant for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. in combination with Inluriyo for the treatment of adults with estrogen receptor (ER)-positive, HER2-negative, estrogen receptor-1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. as monotherapy for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. IMPORTANT SAFETY INFORMATION FOR VERZENIO (abemaciclib)
Severe diarrhea associated with dehydration and infection occurred in patients treated with Verzenio. Across five clinical trials in 3899 patients, diarrhea occurred in 81% to 90% of patients who received Verzenio. Grade 3 diarrhea occurred in 8% to 20% of patients receiving Verzenio. Most patients experienced diarrhea during the first month of Verzenio treatment. The median time to onset of the first diarrhea event ranged from 6 to 8 days; and the median duration of Grade 2 and Grade 3 diarrhea ranged from 6 to 11 days and 5 to 8 days, respectively. Across trials, 19% to 26% of patients with diarrhea required a Verzenio dose interruption and 13% to 23% required a dose reduction.

Instruct patients to start antidiarrheal therapy such as loperamide at the first sign of loose stools, increase oral fluids, and notify their healthcare provider for further instructions and appropriate follow-up. For Grade 3 or 4 diarrhea, or diarrhea that requires hospitalization, withhold Verzenio until resolution to ≤Grade 1, and then resume Verzenio at the next lower dose.

Neutropenia, including febrile neutropenia and fatal neutropenic sepsis, occurred in patients treated with Verzenio. Across five clinical trials in 3899 patients, neutropenia occurred in 37% to 51% of patients receiving Verzenio. A Grade ≥3 decrease in neutrophil count (based on laboratory findings) occurred in 19% to 32% of patients receiving Verzenio.

Across trials, the median time to first episode of Grade ≥3 neutropenia ranged from 29 days to 34 days, and the median duration of Grade ≥3 neutropenia ranged from 10 days to 16 days.

Febrile neutropenia has been reported in <1% of patients exposed to Verzenio across trials. Two deaths due to neutropenic sepsis were observed in MONARCH 2. Inform patients to promptly report any episodes of fever to their healthcare provider.

Monitor complete blood counts prior to the start of Verzenio therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia.

Severe, life-threatening, or fatal interstitial lung disease (ILD) or pneumonitis can occur in patients treated with Verzenio and other CDK4/6 inhibitors. In Verzenio-treated patients in early breast cancer (monarchE, N=2791), 3% of patients experienced ILD or pneumonitis of any grade: 0.4% were Grade 3 or 4 and there was one fatality (0.1%). In Verzenio-treated patients in advanced or metastatic breast cancer (N=1108) (MONARCH 1, MONARCH 2, MONARCH 3, EMBER-3), 3.2% of Verzenio-treated patients had ILD or pneumonitis of any grade: 0.5% had Grade 3 or 4, and 0.5% had fatal outcomes. Additional cases of ILD or pneumonitis have been observed in the postmarketing setting, with fatalities reported.

Monitor patients for pulmonary symptoms indicative of ILD or pneumonitis. Symptoms may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams. Infectious, neoplastic, and other causes for such symptoms should be excluded by means of appropriate investigations.

Withhold or reduce dose for patients who develop persistent or recurrent Grade 2 ILD or pneumonitis. Permanently discontinue VERZENIO in all patients with Grade 3 or 4 ILD or pneumonitis.

Grade ≥3 increases in alanine aminotransferase (ALT) (2% to 6%) and aspartate aminotransferase (AST) (2% to 3%) were reported in patients receiving Verzenio.

Across four clinical trials in 3767 patients (monarchE, MONARCH 2, MONARCH 3, EMBER-3), the median time to onset of Grade ≥3 ALT increases ranged from 57 to 87 days and the median time to resolution to Grade <3 was 13 to 14 days. The median time to onset of Grade ≥3 AST increases ranged from 71 to 185 days and the median time to resolution to Grade <3 ranged from 11 to 15 days.

Monitor liver function tests (LFTs) prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. Dose interruption, dose reduction, dose discontinuation, or delay in starting treatment cycles is recommended for patients who develop persistent or recurrent Grade 2, or any Grade 3 or Grade 4 hepatic transaminase elevation.

Venous thromboembolic events (VTE) were reported in 2% to 5% of patients treated with Verzenio across four clinical trials in 3767 patients (monarchE, MONARCH 2, MONARCH 3, EMBER-3). VTE events included deep vein thrombosis, pulmonary embolism, pelvic venous thrombosis, cerebral venous sinus thrombosis, subclavian and axillary vein thrombosis, inferior vena cava thrombosis, jugular vein thrombosis, peripheral vein thrombosis and superficial vein thrombosis. In clinical trials, deaths due to VTE occurred in patients treated with Verzenio.

Verzenio has not been studied in patients with early breast cancer who had a history of VTE. Monitor patients for signs and symptoms of venous thrombosis and pulmonary embolism and treat as medically appropriate. Dose interruption is recommended for early breast cancer patients with any grade VTE event and for advanced or metastatic breast cancer patients with a Grade 3 or 4 VTE event.

Verzenio can cause fetal harm when administered to a pregnant woman, based on findings from animal studies and the mechanism of action. In animal reproduction studies, administration of abemaciclib to pregnant rats during the period of organogenesis caused teratogenicity and decreased fetal weight at maternal exposures that were similar to the human clinical exposure based on area under the curve (AUC) at the maximum recommended human dose.

Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with Verzenio and for 3 weeks after the last dose.

Verzenio can increase serum creatinine without affecting renal function. These increases were not associated with changes in glomerular function. In EMBER-3, creatinine increase occurred in 36% for all grades (Grade 3 or 4: 1.1%) of patients who received Inluriyo in combination with Verzenio. During Verzenio treatment, use alternative measures that are not based on serum creatinine to assess renal function such as BUN, cystatin C, or calculated GFR.

The most common adverse reactions (all grades, ≥10%) observed in monarchE for Verzenio plus tamoxifen or an aromatase inhibitor vs tamoxifen or an aromatase inhibitor, with a difference between arms of ≥2%, were diarrhea (84% vs 9%), infections (51% vs 39%), neutropenia (46% vs 6%), fatigue (41% vs 18%), leukopenia (38% vs 7%), nausea (30% vs 9%), anemia (24% vs 4%), headache (20% vs 15%), vomiting (18% vs 4.6%), stomatitis (14% vs 5%), lymphopenia (14% vs 3%), thrombocytopenia (13% vs 2%), decreased appetite (12% vs 2.4%), ALT increased (12% vs 6%), AST increased (12% vs 5%), dizziness (11% vs 7%), rash (11% vs 4.5%), and alopecia (11% vs 2.7%).

The most frequently reported ≥5% Grade 3 or 4 adverse reaction that occurred in the Verzenio arm vs the tamoxifen or an aromatase inhibitor arm of monarchE were neutropenia (19.6% vs 1%), leukopenia (11% vs <1%), diarrhea (8% vs 0.2%), and lymphopenia (5% vs <1%).

Lab abnormalities (all grades; Grade 3 or 4) for monarchE in ≥10% for Verzenio plus tamoxifen or an aromatase inhibitor with a difference between arms of ≥2% were increased serum creatinine (99% vs 91%; 0.5% vs <0.1%), decreased white blood cells (89% vs 28%; 19.1% vs 1.1%), decreased neutrophil count (84% vs 23%; 18.7% vs 1.9%), anemia (68% vs 17%; 1% vs .1%), decreased lymphocyte count (59% vs 24%; 13.2% vs 2.5%), decreased platelet count (37% vs 10%; .9% vs .2%), increased ALT (37% vs 24%; 2.6% vs 1.2%), increased AST (31% vs 18%; 1.6% vs .9%), and hypokalemia (11% vs 3.8%; 1.3% vs 0.2%).

The most common adverse reactions (all grades, ≥10%) observed in MONARCH 3 for Verzenio plus anastrozole or letrozole vs anastrozole or letrozole, with a difference between arms of ≥2%, were diarrhea (81% vs 30%), fatigue (40% vs 32%), neutropenia (41% vs 2%), infections (39% vs 29%), nausea (39% vs 20%), abdominal pain (29% vs 12%), vomiting (28% vs 12%), anemia (28% vs 5%), alopecia (27% vs 11%), decreased appetite (24% vs 9%), leukopenia (21% vs 2%), creatinine increased (19% vs 4%), constipation (16% vs 12%), ALT increased (16% vs 7%), AST increased (15% vs 7%), rash (14% vs 5%), pruritus (13% vs 9%), cough (13% vs 9%), dyspnea (12% vs 6%), dizziness (11% vs 9%), weight decreased (10% vs 3.1%), influenza-like illness (10% vs 8%), and thrombocytopenia (10% vs 2%).

The most frequently reported ≥5% Grade 3 or 4 adverse reactions that occurred in the Verzenio arm vs the placebo arm of MONARCH 3 were neutropenia (22% vs 1%), diarrhea (9% vs 1.2%), leukopenia (7% vs <1%)), increased ALT (6% vs 2%), and anemia (6% vs 1%).

Lab abnormalities (all grades; Grade 3 or 4) for MONARCH 3 in ≥10% for Verzenio plus anastrozole or letrozole with a difference between arms of ≥2% were increased serum creatinine (98% vs 84%; 2.2% vs 0%), decreased white blood cells (82% vs 27%; 13% vs 0.6%), anemia (82% vs 28%; 1.6% vs 0%), decreased neutrophil count (80% vs 21%; 21.9% vs 2.6%), decreased lymphocyte count (53% vs 26%; 7.6% vs 1.9%), decreased platelet count (36% vs 12%; 1.9% vs 0.6%), increased ALT (48% vs 25%; 6.6% vs 1.9%), and increased AST (37% vs 23%; 3.8% vs 0.6%).

The most common adverse reactions (all grades, ≥10%) observed in MONARCH 2 for Verzenio plus fulvestrant vs fulvestrant, with a difference between arms of ≥2%, were diarrhea (86% vs 25%), neutropenia (46% vs 4%), fatigue (46% vs 32%), nausea (45% vs 23%), infections (43% vs 25%), abdominal pain (35% vs 16%), anemia (29% vs 4%), leukopenia (28% vs 2%), decreased appetite (27% vs 12%), vomiting (26% vs 10%), headache (20% vs 15%), dysgeusia (18% vs 2.7%), thrombocytopenia (16% vs 3%), alopecia (16% vs 1.8%), stomatitis (15% vs 10%), ALT increased (13% vs 5%), pruritus (13% vs 6%), cough (13% vs 11%), dizziness (12% vs 6%), AST increased (12% vs 7%), peripheral edema (12% vs 7%), creatinine increased (12% vs <1%), rash (11% vs 4.5%), pyrexia (11% vs 6%), and weight decreased (10% vs 2.2%).

The most frequently reported ≥5% Grade 3 or 4 adverse reactions that occurred in the Verzenio arm vs the placebo arm of MONARCH 2 were neutropenia (25% vs 1%), diarrhea (13% vs 0.4%), leukopenia (9% vs 0%), anemia (7% vs 1%), and infections (5.7% vs 3.5%).

Lab abnormalities (all grades; Grade 3 or 4) for MONARCH 2 in ≥10% for Verzenio plus fulvestrant with a difference between arms of ≥2% were increased serum creatinine (98% vs 74%; 1.2% vs 0%), decreased white blood cells (90% vs 33%; 23.7% vs .9%), decreased neutrophil count (87% vs 30%; 32.5% vs 4.2%), anemia (84% vs 34%; 2.6% vs .5%), decreased lymphocyte count (63% vs 32%; 12.2% vs 1.8%), decreased platelet count (53% vs 15%; 2.1% vs 0%), increased ALT (41% vs 32%; 4.6% vs 1.4%), and increased AST (37% vs 25%; 3.9% vs 4.2%).

The most common adverse reactions (all grades, ≥10%) observed in MONARCH 1 with Verzenio were diarrhea (90%), fatigue (65%), nausea (64%), decreased appetite (45%), abdominal pain (39%), neutropenia (37%), vomiting (35%), infections (31%), anemia (25%), thrombocytopenia (20%), headache (20%), cough (19%), constipation (17%), leukopenia (17%), arthralgia (15%), dry mouth (14%), weight decreased (14%), stomatitis (14%), creatinine increased (13%), alopecia (12%), dysgeusia (12%), pyrexia (11%), dizziness (11%), and dehydration (10%).

The most frequently reported ≥5% Grade 3 or 4 adverse reactions from MONARCH 1 with Verzenio were diarrhea (20%), neutropenia (24%), fatigue (13%), and leukopenia (5%).

Lab abnormalities (all grades; Grade 3 or 4) for MONARCH 1 with Verzenio were increased serum creatinine (99%; .8%), decreased white blood cells (91%; 28%), decreased neutrophil count (88%; 26.6%), anemia (69%; 0%), decreased lymphocyte count (42%; 13.8%), decreased platelet count (41%; 2.3%), increased ALT (31%; 3.1%), and increased AST (30%; 3.8%).

Serious and Fatal Adverse Reactions for Inluriyo in combination with Verzenio: Serious adverse reactions occurred in 21% of patients who received Inluriyo in combination with Verzenio. Serious adverse reactions in >1% of patients who received Inluriyo in combination with Verzenio included pneumonia (2.4%), abdominal pain, and renal failure (each 1.4%). Fatal adverse reactions occurred in 3.8% of patients who received Inluriyo in combination with Verzenio, including pneumonia (1.4%), myocardial infarction, interstitial lung disease, and sepsis (0.5% each).

Most Common Adverse Reactions for Inluriyo in combination with Verzenio: The most common (≥10%) adverse reactions with Inluriyo in combination with Verzenio, including laboratory abnormalities, were decreased neutrophils, diarrhea, decreased hemoglobin, decreased lymphocytes, nausea, decreased platelets, fatigue, increased triglycerides, infections, increased AST, increased creatinine, increased ALT, vomiting, musculoskeletal pain, abdominal pain, decreased appetite, increased cholesterol, rash, cough, headache, and decreased weight.

Strong and moderate CYP3A inhibitors increased the exposure of abemaciclib plus its active metabolites to a clinically meaningful extent and may lead to increased toxicity. Avoid concomitant use of ketoconazole. Ketoconazole is predicted to increase the AUC of abemaciclib by up to 16-fold. In patients with recommended starting doses of 200 mg twice daily or 150 mg twice daily, reduce the Verzenio dose to 100 mg twice daily with concomitant use of strong CYP3A inhibitors other than ketoconazole. In patients who have had a dose reduction to 100 mg twice daily due to adverse reactions, further reduce the Verzenio dose to 50 mg twice daily with concomitant use of strong CYP3A inhibitors. If a patient taking Verzenio discontinues a strong CYP3A inhibitor, increase the Verzenio dose (after 3-5 half-lives of the inhibitor) to the dose that was used before starting the inhibitor. Patients should avoid grapefruit products. With concomitant use of moderate CYP3A inhibitors, monitor for adverse reactions and consider reducing the Verzenio dose in 50 mg decrements.

Avoid concomitant use of strong or moderate CYP3A inducers and consider alternative agents. Coadministration of strong or moderate CYP3A inducers decreased the plasma concentrations of abemaciclib plus its active metabolites and may lead to reduced activity.

With severe hepatic impairment (Child-Pugh C), reduce the Verzenio dosing frequency to once daily. No dosage adjustments are necessary in patients with mild or moderate hepatic impairment (Child-Pugh A or B).

Please see full Prescribing Information and Patient Information for Verzenio.

VZ IN HCP ISI ALL APPR

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about sofetabart mipitecan as a potential treatment for ovarian cancer as well as other FRα-expressing solid tumors, olomorasib as a potential treatment for certain KRAS G12C-mutant advanced solid tumors, Retevmo (selpercatinib) as a treatment for advanced RET-mutant medullary thyroid cancer (MTC), and Verzenio (abemaciclib) as a treatment for certain HR+, HER2– breast cancers in the adjuvant and advanced or metastatic setting, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that planned or ongoing studies will be completed as planned, that future study results will be consistent with study results to date, that any of these therapies will prove to be a safe and effective treatment or receive regulatory approval, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Endnotes & References

Bax, Heather J et al. "Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes." British journal of cancer vol. 128,2 (2023): 342-353. doi:10.1038/s41416-022-02031-x  Scaranti, Mariana et al. "Exploiting the folate receptor α in oncology." Nature reviews. Clinical oncology vol. 17,6 (2020): 349-359. doi:10.1038/s41571-020-0339-5.  Kalli, Kimberly R et al. "Folate receptor alpha as a tumor target in epithelial ovarian cancer." Gynecologic oncology vol. 108,3 (2008): 619-26. doi:10.1016/j.ygyno.2007.11.020.  Viricel W, et al. Cancer Res. 2023;83(suppl 7):1544.  Ji J, Wang C, Fakih M. Targeting KRAS G12C-mutated advanced colorectal cancer: Research and clinical developments. OncoTargets and Therapy. 2022;Volume 15:747-756. doi:10.2147/ott.s340392 Peng S-B, Si C, Zhang Y, et al. Abstract 1259: Preclinical characterization of LY3537982, a novel, highly selective and potent KRAS-G12C inhibitor. Cancer Research. 2021;81(13_Supplement):1259-1259. doi:10.1158/1538-7445.am2021-1259 Retevmo. Prescribing information. Lilly USA, LLC. Verzenio. Prescribing information. Lilly USA, LLC. Inluriyo. Prescribing information. Lilly USA, LLC. Refer to:  Megan Talon; [email protected] (Media)
                 Michael Czapar; [email protected] (Investors)

SOURCE Eli Lilly and Company

You don't have to look hard to find signs that the stock market's run is in a precarious position. One example: Warren Buffett's favorite market valuation metric is well above the level at which he has previously warned that investors are "playing with fire."

It's never a good idea to panic if a storm is potentially on the horizon. Instead, prudent investors take wide precautionary steps to be prepared.

Looking to the past to see which investments have held up better than others can be especially instructive. If a stock market crash is coming, history shows that these three exchange-traded funds (ETFs) rank among the smartest choices.

Image source: Getty Images.

1. Schwab U.S. Dividend Equity ETF
The Schwab U.S. Dividend Equity ETF (SCHD +0.73%) has become a favorite among income investors for good reason. It pays a solid 3.3% dividend yield and has paid regular quarterly distributions since its inception 15 years ago.

However, this ETF isn't only a good pick for income investors if a stock market crash is around the corner. The quality of the 102 stocks in the Schwab U.S. Dividend Equity ETF's portfolio makes the fund one of the better defensive investment alternatives around.

SCHD Schwab U.S. Dividend Equity ETF$34.35+$0.25 (+0.73%)

NYSEMKT · As of 4:00 PM ET 10/16/26

The ETF attempts to track the performance of the Dow Jones U.S. Dividend 100 Index. This index focuses on U.S. stocks that consistently pay dividends with attractive yields and are fundamentally strong compared to their peers.

Roughly 41% of the Schwab U.S. Dividend Equity ETF's holdings are consumer staples and healthcare stocks. Both sectors tend to outperform most others during steep market downturns.

2. Health Care Select Sector SPDR Fund
Speaking of healthcare, the State Street Health Care Select Sector SPDR Fund (XLV -0.27%) offers one of the easiest ways to invest in the sector. This ETF holds 60 of the largest healthcare stocks, with top holdings including Eli Lilly (LLY +0.43%), Johnson & Johnson (JNJ +0.90%), AbbVie (ABBV +0.71%), Merck (MRK +0.52%), and UnitedHealth Group (UNH -1.29%).

The State Street Health Care Select Sector SPDR Fund has handily outperformed the S&P 500 (^GSPC -1.09%) over the last 12 months. That isn't surprising considering the rising uncertainty that investors are facing.

XLV Select Sector SPDR Trust - State Street Health Care Select Sector SPDR ETF$176.71-$0.48 (-0.27%)

NYSEMKT · As of 4:00 PM ET 10/16/26

People don't stop taking medications or forego seeking medical treatment for serious issues because the stock market falls. As a result, healthcare companies' businesses tend to be highly resilient.

To be sure, the State Street Health Care Select SPDR Fund isn't immune to market downturns. For example, the ETF declined when the dot-com bubble burst in 2000 and in the financial crisis of 2008. However, its pullback was much less severe, and it recovered much more quickly than the overall market in both periods.

3. SPDR Bloomberg 1-3 Month T-Bill ETF
What's Warren Buffett's favorite investment when turbulence is likely? Short-term Treasury bonds. Roughly $325 billion of Berkshire Hathaway's (BRKA +1.08%) (BRKB +1.21%) cash was parked in short-term Treasuries as of the end of the second quarter. The State Street SPDR Bloomberg 1-3 Month T-Bill ETF (BIL +0.03%) provides a straightforward way for investors who aren't billionaires to follow Buffett's lead.

As its name indicates, this ETF offers exposure to U.S. Treasury bills with remaining maturities between one and three months. It attempts to track the performance of the Bloomberg 1-3 Month U.S. Treasury Bill Index.

BIL SPDR Series Trust - State Street SPDR Bloomberg 1-3 Month T-Bill ETF$91.57+$0.03 (+0.03%)

NYSEMKT · As of 4:00 PM ET 10/16/26

The State Street SPDR Bloomberg 1-3 Month T-Bill ETF currently pays a distribution yield above 4%. And because the Treasuries it owns are so short-duration, it isn't experiencing the volatility that many bond funds are these days as interest rates rise.

This fund won't deliver tremendous returns if the stock market crashes. What it will do, though, is protect investors' capital and generate reliable income while they wait for great opportunities to buy stocks at a discount. This approach has worked quite well for Buffett through the years.

Eli Lilly's (LLY +0.43%) Zepbound, an anti-obesity medicine, was first approved in the U.S. in 2023. It has become one of the company's main growth drivers ever since and is now the top-selling drug in the chronic weight management landscape. Zepbound could remain one of the most important therapies in Eli Lilly's arsenal, given that the weight-loss market is growing rapidly. However, the drugmaker has several other medicines that could help power its next era of growth. Let's consider three of them.

Image source: The Motley Fool.

1. Foundayo
Foundayo is an oral GLP-1 medicine approved for weight loss. It first earned approval in the U.S. in April and has been fairly successful since. What's important about Foundayo is that it isn't just cannibalizing Zepbound's sales. Earlier this year, Eli Lilly noted that 80% of prescriptions for Foundayo were for patients who had never taken GLP-1 medicines before.

That makes sense. Zepbound is administered once weekly via subcutaneous injection. Some patients simply dislike needles. It also has storage requirements that, while not overly stringent, can be inconvenient for some patients, especially those who travel regularly. These factors likely helped Eli Lilly attract a new audience with Foundayo.

True, the medicine is trailing the Wegovy pill in the oral weight loss market. But Foundayo could gain significant traction over the medium term. Here are two reasons why. First, it can be taken at any time of day without food or water restrictions. By contrast, oral Wegovy is taken first thing in the morning on an empty stomach.

Second, and perhaps more importantly, Foundayo will likely earn important label expansions, including in diabetes, obstructive sleep apnea, and several other indications. These could help boost the medicine's sales over the next few years.

2. Onswik
Eli Lilly earned approval for Onswik, a diabetes medicine, in September. Onswik is a once-weekly basal insulin injection which, in clinical trials, showed efficacy comparable to that of daily insulin medicines. Of course, Onswik is much more convenient since it significantly reduces the number of doses per year. So, it could attract a decent number of patients.

Onswik isn't the first once-weekly insulin medicine to earn approval. That was Novo Nordisk's (NVO -0.99%) Awiqli, which earned approval in the U.S. in March. Still, the launch of Onswik should strengthen Eli Lilly's already strong diabetes portfolio.

$1,257.03+$5.42 (+0.43%)

NYSE · As of 4:00 PM ET 10/16/26

3. Retatrutide
Retatrutide is the only one of Eli Lilly's next-gen drugs discussed here that has yet to earn approval. However, it could be the most promising. Retatrutide is an investigational weight-loss medicine that mimics the actions of three gut hormones: GLP-1, GIP, and glucagon. Here's why that's significant. Zepbound's market-leading efficacy is partly attributed to its ability to mimic two gut hormones, GLP-1 and GIP, whereas its main competitor, Wegovy, mimics only GLP-1.

But retatrutide goes one step further than Zepbound, which could, in theory, lead to even stronger efficacy. The data so far appear to support that theory. In one Phase 3 study, retatrutide led to an average weight loss of up to 28.3% over 80 weeks.

It has also shown tremendous promise in helping patients with diabetes lose weight (which is typically harder for them), as well as in other indications, such as obstructive sleep apnea. Retatrutide shouldn't simply cannibalize Zepbound's sales either -- it could attract newer patients, including those with very high BMIs (body mass indexes) who have had trouble losing weight even with the currently available options. Retatrutide could become one of Eli Lilly's key growth drivers. The pharmaceutical company plans to submit regulatory applications for the drug in the first quarter of 2027.

Buy and forget
This is not an exhaustive list of Eli Lilly's promising drugs and pipeline candidates. Others, such as eloralintide, an investigational drug for weight loss, Kisunla, a medicine approved for Alzheimer's disease (AD), and remternetug, which is being developed for AD, look promising as well. Eli Lilly will face more competition in the weight loss market in the coming years, but the company's pipeline across weight loss, diabetes, and other areas could allow it to remain one of the leaders in its core market while making significant progress in others. That's why, even though it has crushed broader equities in recent years, Eli Lilly remains one of the top healthcare stocks to buy.

, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2026 financial results on October 29, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.  

The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call.  

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. F-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are references in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Refer to:  Megan MacCauley; [email protected] (Media)
                 Mike Czapar; [email protected] (Investors)

SOURCE Eli Lilly and Company

In LUCENT-2, more than one in four (27.7%) Omvoh-treated patients with ulcerative colitis achieved comprehensive disease control, a novel composite outcome defined by simultaneous symptomatic, endoscopic and histologic remission, biomarker normalization and no corticosteroid use

In VIVID-1, one in five (20.4%) Omvoh-treated patients with Crohn's disease achieved corticosteroid-free deep remission, a composite outcome defined by simultaneous clinical remission, endoscopic remission and no corticosteroid use
 

Across both types of inflammatory bowel disease, including patients with prior biologic failure, achieving comprehensive disease control or corticosteroid-free deep remission was associated with improved patient-reported outcomes

, /PRNewswire/ -- New data analyses from Eli Lilly and Company (NYSE: LLY) show patients with moderately to severely active ulcerative colitis (UC) and Crohn's disease treated with Omvoh (mirikizumab-mrkz) achieved multiple treatment goals simultaneously at one year, as measured by comprehensive disease control in UC and corticosteroid-free deep remission in Crohn's disease. These multidimensional outcomes were observed even in patients with prior biologic failure, a population often facing greater treatment challenges. More than one-third of patients in the UC analysis and nearly half of patients in the Crohn's disease analysis had previously experienced biologic treatment failure. Furthermore, patients who achieved these endpoints were more likely to also achieve remission on the Inflammatory Bowel Disease Questionnaire (IBDQ), a validated patient-reported measure of health-related quality of life. Together, these findings reflect an evolution of treatment goals in inflammatory bowel disease (IBD), looking across symptoms, inflammation and impact of disease on daily life to support a more holistic, patient-centered approach that goes beyond clinical remission. These post-hoc data from the LUCENT and VIVID programs will be presented at United European Gastroenterology (UEG) Week 2026.1,2

"Treatment in inflammatory bowel disease is often measured one endpoint at a time. These new data show that patients treated with Omvoh achieved multiple treatment goals simultaneously at one year, including those with prior biologic failure, and were more likely to report better quality of life," said Anabela Cardoso, senior vice president, Lilly Immunology Medical Affairs. "These findings reinforce the impact that Omvoh can have for people living with ulcerative colitis and Crohn's disease and show that a higher bar for disease control is achievable."

A comprehensive approach to IBD management considers multiple dimensions of disease, including the symptoms patients experience, what clinicians can objectively measure and how disease affects daily life.3-4 In previously published real-world studies, improvements across multiple dimensions of disease have been associated with a lower risk of flares, steroid use, hospitalization and surgery over time.4-7

"Inflammatory bowel disease is complex, and understanding treatment impact requires a broader view than any single endpoint can provide. These endpoints reflect a meaningful shift in how we define treatment success," said Stefan Schreiber, M.D., University Hospital Schleswig-Holstein, Christian-Albrecht University of Kiel. "Across the LUCENT and VIVID programs, Omvoh-treated patients achieved multidimensional treatment outcomes, including comprehensive disease control in ulcerative colitis and corticosteroid-free deep remission in Crohn's disease. Importantly, these outcomes were also observed in patients with prior biologic failure."

Comprehensive disease control with Omvoh in ulcerative colitis
Comprehensive disease control is a novel composite outcome, informed by an international expert consensus3, that combines clinical remission*, no corticosteroid use for at least 12 weeks before Week 52, histologic remission† and fecal calprotectin ≤250 μg/g. Omvoh is the first IL-23p19 inhibitor evaluated for comprehensive disease control in UC, reflecting an evolving approach to treatment goals that goes beyond individual measures of disease activity for people living with UC. 

Comprehensive disease control was evaluated in a post hoc analysis at one year in patients with UC who responded to Omvoh at Week 12 in the LUCENT-1 induction study and were re-randomized in LUCENT-2 to continue Omvoh or receive placebo. More than one-third of patients (35.3%) had previously experienced biologic treatment failure.

At one year:1 

27.7% of patients treated with Omvoh achieved comprehensive disease control compared with 14% receiving placebo.‡ Among patients with prior biologic failure, 23.4% of those treated with Omvoh achieved comprehensive disease control compared with 9.4% receiving placebo.‡ Among Omvoh-treated patients, 91.1% of those who achieved comprehensive disease control also achieved IBDQ remission§, compared with 65.2% of those who did not achieve comprehensive disease control. Omvoh-treated patients who achieved comprehensive disease control were also more likely to report no to minimal bowel urgency (bowel urgency remission) and greater improvements in work productivity than those who did not achieve comprehensive disease control.∥  Corticosteroid-free deep remission with Omvoh in Crohn's disease
Corticosteroid-free deep remission was evaluated in a post hoc analysis at one year in patients with Crohn's disease in VIVID-1. Nearly half of patients (48.6%) had previously experienced biologic treatment failure. Corticosteroid-free deep remission is a composite outcome that combines clinical remission (as measured by the Crohn's Disease Activity Index), endoscopic remission and no corticosteroid use for at least 12 weeks before Week 52.¶

At one year:2 

20.4% of patients receiving Omvoh achieved corticosteroid-free deep remission compared with 2% receiving placebo.# Among patients with prior biologic failure, 15.7% of those treated with Omvoh achieved corticosteroid-free deep remission compared with none of those receiving placebo.# Among Omvoh-treated patients, 88.1% of those who achieved corticosteroid-free deep remission also achieved IBDQ remission§, compared with 51% of those who did not achieve corticosteroid-free deep remission. The safety findings observed in the Phase 3 LUCENT and VIVID clinical trial programs have been reported previously. The most common adverse reactions associated with Omvoh treatment in LUCENT-1 and -2 (reported in at least 2% of subjects at a higher frequency than placebo) were upper respiratory tract infections, injection site reactions, arthralgia, rash, headache and herpes viral infection. In VIVID-1, the most common adverse reactions associated with Omvoh treatment (reported in at least 5% of subjects at a higher frequency than placebo) were upper respiratory tract infections, injection site reactions, headache, arthralgia and elevated liver tests.8

Omvoh has received regulatory approvals for the treatment of moderately to severely active UC and moderately to severely active Crohn's disease in adults and has been approved in 47 countries. Omvoh is also approved as a single-injection maintenance regimen for adults with UC in several countries around the world, including the U.S., EU, Canada and Japan.

Lilly continues to advance the standard of care in gastroenterology through the next wave of immunology innovation, including combination approaches, novel mechanisms and the potential of incretins. Lilly is pursuing combination studies of mirikizumab aimed at delivering breakthrough induction efficacy while maintaining long-term remission and safety. These include studies in UC with eltrekibart (NCT06598943), a monoclonal antibody that targets neutrophil-driven inflammation, and with zotemtegrast (NCT07186101), an oral α4β7 integrin inhibitor. In Crohn's disease, Lilly is studying mirikizumab in combination with an FXR agonist (NCT07483099). The COMMIT-UC (NCT06937086) and COMMIT-CD (NCT06937099) trials are investigating the concomitant use of mirikizumab and an incretin-based therapy in adults with UC or Crohn's disease and obesity or overweight with at least one additional weight-related comorbid condition. In addition, trials of mirikizumab in pediatric patients are ongoing, including a long-term extension study in UC and Crohn's disease (NCT04844606) and an ongoing Phase 3 study in pediatric Crohn's disease (NCT05509777).

About the LUCENT Clinical Trial Program
Omvoh was studied in two Phase 3 clinical trials which evaluated the efficacy and safety of Omvoh in adults with moderately to severely active UC, in both biologic-naïve patients and those who had previously failed a biologic or Janus kinase inhibitor (JAKi).

The randomized, double-blind, placebo-controlled LUCENT-1 (induction) study included patients with an inadequate response, loss of response, or intolerance to corticosteroids, immunomodulators, biologic therapy, or JAKi, and LUCENT-2 (maintenance) evaluated continued treatment versus placebo in patients who achieved a clinical response to Omvoh in LUCENT-1.

About the VIVID Clinical Trial Program
VIVID-1 was a Phase 3 randomized, double-blind, placebo-controlled 52-week study in adults with moderately to severely active Crohn's disease. Patients randomized to Omvoh received Omvoh 900 mg by intravenous (IV) infusion at Week 0, Week 4 and Week 8, followed by a maintenance dose of 300 mg by subcutaneous injection (SC) at Week 12 and then every four weeks (Q4W) for 40 weeks.

About Omvoh
Omvoh (mirikizumab-mrkz) is an interleukin-23p19 (IL-23p19) antagonist indicated for the treatment of moderately to severely active ulcerative colitis and Crohn's disease in adults. Omvoh selectively targets the p19 subunit of IL-23 and inhibits the IL-23 pathway. Inflammation due to over-activation of the IL-23 pathway plays a critical role in the pathogenesis of inflammatory bowel disease.8

Omvoh and its delivery device base are trademarks owned by Eli Lilly and Company.

Endnotes and References
*Clinical remission (based on the modified Mayo score [mMS]): stool frequency subscore=0 or 1 with a ≥1-point decrease from baseline, and rectal bleeding subscore=0, and endoscopic subscore (ES)=0 or 1 (excluding friability).
†Histologic remission: Geboes subscores of 0 for grades 2b (neutrophils in lamina propria), 3 (neutrophils in epithelium), 4 (crypt destruction) and 5 (erosion or ulceration).
‡In LUCENT-2, patients randomized to placebo had achieved clinical response with Omvoh during LUCENT-1 induction and were then re-randomized to discontinue from Omvoh and receive placebo through the maintenance period. Patients randomized to Omvoh continued treatment, for a total of 52 weeks from induction baseline.
§Inflammatory Bowel Disease Questionnaire (IBDQ) remission: total score ≥170.
∥No to minimal bowel urgency (bowel urgency remission) was defined as an Urgency NRS score of 0 or 1; work productivity assessed using the Work Productivity and Activity Impairment Questionnaire for UC (WPAI).
¶Corticosteroid-free Crohn's Disease Activity Index (CDAI)-based deep remission: CDAI <150, endoscopic remission (SES-CD ≤4 and ≥2-point reduction from baseline with no subscore >1) and no corticosteroid use during the 12 weeks before Week 52.
#Patients receiving placebo in VIVID-1 were randomized to placebo at baseline. Those who did not respond by Week 12 switched to Omvoh and were counted as non-responders in this analysis.

1Schreiber S, et al. Mirikizumab therapy enables comprehensive disease control with improved quality of life in patients with moderately-to-severely active ulcerative colitis: a post-hoc analysis of Phase 3 LUCENT-1 and LUCENT-2 trials. American College of Gastroenterology (ACG) Annual Scientific Meeting; October 11, 2026; Nashville, TN. P-1182.
2Schreiber S, et al. Mirikizumab effect on deep remission with improved quality of life in moderately to severely active Crohn's disease: a post hoc analysis from VIVID-1. United European Gastroenterology Week 2026;. October 18, 2026; Barcelona, Spain. MP0290.
3Schreiber, S, Danese, S, Dignass, A, et al. Defining comprehensive disease control for use as a treatment target for ulcerative colitis in clinical practice: International Delphi consensus recommendations. J Crohns Colitis. 2024;18(1):91–105. https://doi.org/10.1093/ecco-jcc/jjad130
4Fanizzi, F, D'Amico, F, Peyrin-Biroulet, L, Danese, S, & Dignass, A. Treatment targets in IBD: Is it time for new strategies? Best Pract Res Clin Gastroenterol. 2025;77:101990. https://doi.org/10.1016/j.bpg.2025.101990
5Shehab M, et al. Histological disease activity as predictor of clinical relapse, hospitalization, and surgery in inflammatory bowel disease: systematic review and meta-analysis. Inflamm Bowel Dis. 2024;30(4):563-572. doi:10.1093/ibd/izad119
6Andronic AM, Toader E. P398 Disease clearance: a potential target for management of patients with ulcerative colitis. J Crohns Colitis. 2023;17(Suppl 1):i529. doi:10.1093/ecco-jcc/jjac190.0528
7Pai RK, D'Haens G, Kobayashi T, et al. Histologic assessments in ulcerative colitis: the evidence behind a new endpoint in clinical trials. Expert Rev Gastroenterol Hepatol. 2024;18(1-3):73-87. doi:10.1080/17474124.2024.2326838
8Omvoh. Prescribing Information. Lilly USA, LLC.

Indications and Usage for Omvoh® (mirikizumab-mrkz) (in the United States)
Omvoh is an interleukin-23 antagonist indicated for adults with:

Moderately to severely active ulcerative colitis Moderately to severely active Crohn's disease Important Safety Information for Omvoh (mirikizumab-mrkz)

CONTRAINDICATIONS

Omvoh is contraindicated in patients with a history of serious hypersensitivity reaction to mirikizumab-mrkz or any of the excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions
Serious hypersensitivity reactions, including anaphylaxis during intravenous infusion, have been reported with Omvoh administration. Infusion-related hypersensitivity reactions, including mucocutaneous erythema and pruritus, were reported during induction. If a severe hypersensitivity reaction occurs, discontinue Omvoh immediately and initiate appropriate treatment.

Infections
Omvoh may increase the risk of infection. Do not initiate treatment with Omvoh in patients with a clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing Omvoh. Instruct patients to seek medical advice if signs or symptoms of clinically important acute or chronic infection occur. If a serious infection develops or an infection is not responding to standard therapy, monitor the patient closely and do not administer Omvoh until the infection resolves.

Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Omvoh. Do not administer Omvoh to patients with active TB infection. Initiate treatment of latent TB prior to administering Omvoh. Consider anti-TB therapy prior to initiation of Omvoh in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after Omvoh treatment. In clinical trials, subjects were excluded if they had evidence of active TB, a history of active TB, or were diagnosed with latent TB at screening.

Hepatotoxicity
Drug-induced liver injury in conjunction with pruritus was reported in a clinical trial subject following a longer than recommended induction regimen. Omvoh was discontinued. Liver test abnormalities eventually returned to baseline. Evaluate liver enzymes and bilirubin at baseline and for at least 24 weeks of treatment. Monitor thereafter according to routine patient management. Consider other treatment options in patients with evidence of liver cirrhosis. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury. Interrupt treatment if drug-induced liver injury is suspected, until this diagnosis is excluded. Instruct patients to seek immediate medical attention if they experience symptoms suggestive of hepatic dysfunction.

Immunizations
Avoid use of live vaccines in patients treated with Omvoh. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating therapy, complete all age-appropriate vaccinations according to current immunization guidelines. No data are available on the response to live or non-live vaccines in patients treated with Omvoh.

ADVERSE REACTIONS
Most common adverse reactions associated with Omvoh (≥2% of subjects and at a higher frequency than placebo) in ulcerative colitis treatment are upper respiratory tract infections and arthralgia during the induction study (UC-1), and upper respiratory tract infections, injection site reactions, arthralgia, rash, headache, and herpes viral infection during the maintenance study (UC-2). Most common adverse reactions associated with Omvoh in the Crohn's disease study (CD-1) (≥5% of subjects and at a higher frequency than placebo) are upper respiratory tract infections, injection site reactions, headache, arthralgia, and elevated liver tests.

Omvoh injection is available as a 300 mg/15 mL solution in a single-dose vial for intravenous infusion, and as a 100 mg/mL solution or a 200 mg/2 mL solution in a single dose prefilled pen or prefilled syringe for subcutaneous injection. Refer to the Prescribing Information for dosing information.

MR HCP ISI CD APP

Click to access provided Prescribing Information and Medication Guide. See Instructions for Use provided with the device.

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Omvoh (mirikizumab-mrkz) as a treatment for people with moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development and commercialization. Among other things, there is no guarantee that future study results will be consistent with the results to date, or that Lilly will execute its strategies as planned. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

SOURCE Eli Lilly and Company

Healthcare investors often face a choice between steady value and high-octane growth. Choosing between Bristol Myers Squibb (BMY -1.58%) and Eli Lilly & Co. (LLY -1.36%) requires weighing current income against future potential.

Bristol Myers Squibb focuses on specialized medicines for cancer and heart disease, often appealing to value-oriented investors. Eli Lilly & Co. has recently transformed into a growth powerhouse through its leadership in weight-loss and metabolic health. Comparing these two giants helps clarify which path aligns better with your financial goals.

Bristol Myers Squibb is a global biopharmaceutical company that focuses on discovering and delivering medicines for serious conditions, particularly in oncology and immunology. The company distributes its products through wholesalers, distributors, and specialty pharmacies across major global markets including the United States, Europe, and Japan. A December 2025 agreement with the U.S. government regarding drug pricing and supply has already begun to impact its strategy for key medications like Eliquis.

In FY 2025, revenue reached about $48.2 billion, representing a slight decline of roughly 0.2% compared to the prior year. The company reported net income of approximately $7.1 billion and a net margin of roughly 14.6%, demonstrating a significant recovery from its net loss of roughly $8.9 billion in 2024. This performance highlights its established position among pharmaceutical stocks.

As of its December 2025 balance sheet, the debt-to-equity ratio is roughly 2.6x. This metric measures total debt relative to shareholder equity, while the current ratio of nearly 1.3x compares assets to liabilities due within a year. Free cash flow, or cash from operations minus capital expenditures, is approximately $12.8 billion.

The case for Eli Lilly & Co.Eli Lilly & Co. develops and markets a wide range of medicines worldwide, with a significant recent emphasis on metabolic health, obesity, and diabetes treatments. The company serves these markets through account managers and major wholesale distributors like McKesson Corp. (MCK +0.64%), Cencora (COR +1.55%), and Cardinal Health (CAH +0.69%). Additionally, the company has expanded its reach through LillyDirect, a digital platform that provides patients with direct access to medicines.

In FY 2025, revenue climbed to around $65.2 billion, which is an increase of approximately 45% over the previous year. Net income for the period reached close to $21 billion, more than doubling the prior year result. This performance resulted in a net margin of roughly 32%, which measures how much profit the company keeps for every dollar of sales generated.

As of its December 2025 balance sheet, the debt-to-equity ratio is approximately 1.6x. This ratio measures total debt against shareholder equity, while the current ratio of close to 1.6x indicates the ability to cover short-term obligations using current assets. Free cash flow for the fiscal year ended in December 2025 reached nearly $9.0 billion.

Risk profile comparisonBristol Myers Squibb faces pricing pressure from the Inflation Reduction Act and reimbursement restrictions. Pipeline risk remains high as the company seeks to replace revenue from drugs losing patent protection. Recent patent litigation includes a revived $6.7 billion lawsuit and challenges with Cytokinetics (CYTK -1.86%).

Eli Lilly is subject to global pricing controls that affect major products like Jardiance and Trulicity. Intense competition from generic and biosimilar manufacturers continues to challenge branded revenue growth. Supply chain complexities and a reliance on third-party suppliers also present potential operational risks.

Valuation comparisonBristol Myers Squibb trades at a much lower multiple of future earnings estimates than its peer, offering a distinct value proposition. The Forward P/E measures price relative to future earnings estimates, while the P/S ratio compares market cap to sales over the past twelve months.

MetricBristol-Myers SquibbEli Lilly andForward P/E8.2x33.8xP/S ratio2.4x14.1xValuation metrics include sourcing from Financial Modeling Prep (FMP) and may differ from other data providers.

Which stock would I buy in 2026?Eli Lilly is riding a wave of success with its GLP-1 drugs Zepbound for weight loss and Mounjaro, which is the same drug for diabetes control. There is still plenty of growth left in the treatment, and that is expected to power revenue up more than 30% in 2026, to $88.6 billion, with close to $31.4 billion in net income. Its next weight-loss drug, Retatrutide, is hotly anticipated for its triple-agonist approach, which is expected to exceed the weight-loss results of Zepbound. The company is also targeting less affluent customers with a lower-cost GLP pill called Foundayo, which it sells directly to consumers.

Besides GLP-1s, Lilly is working on a small interfering RNA therapeutic targeting lipoprotein(a) for the prevention of atherosclerotic cardiovascular disease in patients with elevated lipoprotein(a) levels. Analysts believe it will be a blockbuster ($1 billion or more in lifetime revenue) if approved.

Bristol Myers Squibb has made positive strides, with its newer growth brands gaining traction and some interesting candidates in the pipeline. The stock is cheap, and that seems to be for good reason. Investors have already priced in much of the upcoming difficulty, which softens the downside but does not make it an obvious buy right now. Bristol Myers Squibb's recovery timeline is hard to predict.

Revenue for the current fiscal year should edge up 3% to $49.9 billion, with a much healthier rise in net income of more than 40% to $11.2 billion.

Bristol Myers has an attractively low forward price-to-earnings and sales ratios, but of course, that reflects some continued rough sailing ahead.

The choice between these two is simple: Eli Lilly has made itself the leader in GLP-1 treatments, and it appears to have a long runway ahead of it in that sector. Bristol Myers has potential, but in this case it's worth paying the premium to grab hold of Lilly's fast growth.

Eli Lilly trades at a premium multiple, yet its revenue growth dwarfs every major pharma peer by a wide margin. Whether that gap justifies buying shares near all-time highs depends on one critical assumption about Lilly's pipeline.

Our 24/7 Wall St. price target for Eli Lilly (NYSE:LLY | LLY Price Prediction) is $1,378.50. That points to 17.83% upside from the current $1,169.93. Our model rates the stock a buy, with high confidence.

24/7 Wall St. Price Target Summary Metric Value Current Price $1,169.93 Price Target from 24/7 Wall St. $1,378.50 Upside/Downside 17.83% Recommendation BUY Confidence Level 90% Lilly trades at 24x forward earnings while revenue grew 47.7% year over year last quarter. For a stock with a trillion-dollar market cap, that multiple looks modest against the growth. Management has raised 2026 revenue guidance twice, to $85B-$87B, and plans to submit retatrutide in Q1 2027.

Lilly Climbs Back Toward Its Highs After Another Guidance Raise Shares are up 1.81% over the past week, 4.16% over the past month, 9.46% year to date and 39.3% over the past year. The stock sits about 9.5% below its 52-week high of $1,292.65 and 50.2% off its low of $778.94.

Q2 revenue reached $22.97B, ahead of the $20.69B estimate. EPS of $8.38 beat the $6.58 consensus. Mounjaro brought in $9.94B (+91%) and Zepbound $4.93B (+46%).

Since the report, the FDA has approved the once-weekly insulin Onswik and expanded Jaypirca’s label into previously untreated CLL. Lilly has also broken ground on a Houston plant, one of ten U.S. manufacturing sites announced since 2020.

Why Bulls See $1,437 and Beyond Lilly’s pipeline goes well past Mounjaro and Zepbound. In Q2, Foundayo prescribers grew from about 8,000 to 36,000. Medicare’s GLP-1 Bridge Program now covers 20 million eligible Americans at $50 per month.

Analysts expect 2027 EPS of $47.5925, and the high estimate reaches $54.94. The consensus target is $1,330.25, supported by 6 Strong Buy ratings plus 19 Buy ratings. In our bull scenario, the stock reaches $1,437.

Pricing Pressure Is the Risk Worth Watching Lilly’s U.S. price fell 9% in Q2 when rebate estimate adjustments are excluded. Management says rising volume will more than offset lower prices, calling the decline “very much embedded in our guide.” Acquired IPR&D charges of $3.03 per share also cut into Q2 EPS.

Those charges came from one-time deals that added to the pipeline. Retatrutide’s filing pathway still faces litigation over how the drug is classified. Analysts include 1 Sell and 1 Strong Sell rating. The bear case is $1,175.26.

How Lilly Compares to Novo Nordisk and AbbVie Novo Nordisk (NYSE:NVO) is Lilly’s direct GLP-1 rival. The stock trades at 12x forward earnings, but its revenue grew just 2.1% last quarter, and earnings declined 20.6%.

AbbVie (NYSE:ABBV) is a large pharma name with a strong immunology franchise. The shares trade at 16x forward earnings on 10.2% revenue growth.

Company Forward P/E Quarterly Revenue Growth YoY Eli Lilly 24x 47.7% Novo Nordisk 12x 2.1% AbbVie 16x 10.2% Lilly’s premium multiple comes with several times the revenue growth of either peer. Against that background, the 24/7 Wall St. price target looks reasonable.

Growth Outruns the Multiple, So Lilly Rates a Buy Our 24/7 Wall St. price target of $1,378.50 carries a buy rating with 90% confidence. What tips the scale for me is earnings momentum.

The case gets stronger if Foundayo keeps gaining share and retatrutide is filed on schedule. It weakens if price cuts start to outpace volume growth. On the current data, I think Lilly’s valuation understates its growth.

Here is where our model projects Lilly could trade at each year-end if current growth trends and market conditions hold.

Year Price Target from 24/7 Wall St. 2026 $1,221.61 2027 $1,417.01 2028 $1,596.31 2029 $1,747.66 2030 $1,853.50 The projections rest on Lilly continuing to execute its current strategy. Retatrutide’s approval, or deeper GLP-1 price cuts, could move the stock well above or below these figures.

Contact [email protected] for any questions or corrections.

NorthCrest Asset Manangement LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 4.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 18,180 shares of the company’s stock after purchasing an additional 751 shares during the quarter. NorthCrest Asset Manangement LLC’s holdings in Eli Lilly and Company were worth $21,263,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Coastal Bridge Advisors LLC acquired a new position in Eli Lilly and Company during the second quarter worth about $2,959,000. Mosaic Family Wealth Partners LLC lifted its holdings in shares of Eli Lilly and Company by 70.6% in the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company’s stock valued at $4,144,000 after purchasing an additional 1,430 shares in the last quarter. Moran Wealth Management LLC grew its position in shares of Eli Lilly and Company by 85.6% in the second quarter. Moran Wealth Management LLC now owns 20,903 shares of the company’s stock valued at $25,072,000 after purchasing an additional 9,638 shares during the last quarter. Generali Investments Management Co LLC grew its position in shares of Eli Lilly and Company by 17.5% in the second quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company’s stock valued at $12,258,000 after purchasing an additional 1,521 shares during the last quarter. Finally, Amundi increased its stake in shares of Eli Lilly and Company by 9.9% during the 1st quarter. Amundi now owns 5,055,025 shares of the company’s stock worth $4,649,464,000 after purchasing an additional 454,549 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Key Eli Lilly and Company News Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Analysts expect Eli Lilly to generate as much as $87 billion in 2026 revenue, driven by Zepbound, diabetes treatments, and its expanding obesity-drug portfolio. The company’s pipeline, including next-generation weight-loss candidates, strengthens the long-term growth outlook. Eli Lilly Expects Up to $87 Billion in 2026 Revenue Positive Sentiment: Royal Bank of Canada reiterated its Outperform rating and set a $1,500 price target, implying substantial upside from the reference price. Wall Street’s overall rating remains “Moderate Buy.” Eli Lilly Outperform Rating Reiterated Positive Sentiment: Phase 3b data for Taltz combined with Zepbound showed stronger skin-clearance and weight-loss results than standard treatment, potentially expanding Lilly’s cardiometabolic opportunity. Eli Lilly Phase 3b Win Neutral Sentiment: A potential stock split is receiving attention because LLY trades above $1,000, but management has not announced one; a split would not change the company’s underlying value. Will Eli Lilly Do a Stock Split Negative Sentiment: A drug combination produced more weight loss than Zepbound alone, but discontinuation rates were considerably higher. That raises questions about tolerability, adherence, and the commercial potential of the regimen. Drug Combination Generated More Weight Loss Negative Sentiment: LLY’s recent pullback reflects profit-taking after a major rally, while its high valuation leaves the shares sensitive to any slowdown in obesity-drug growth or disappointing clinical data. Eli Lilly Stock Has Pulled Back Eli Lilly and Company Stock Performance NYSE:LLY opened at $1,183.51 on Tuesday. The firm has a 50 day simple moving average of $1,175.57 and a 200-day simple moving average of $1,100.31. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The firm has a market cap of $1.11 trillion, a PE ratio of 39.72, a P/E/G ratio of 1.47 and a beta of 0.46. Eli Lilly and Company has a 1-year low of $783.85 and a 1-year high of $1,292.65. Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. Eli Lilly and Company’s revenue was up 47.7% compared to the same quarter last year. During the same quarter last year, the business earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities analysts expect that Eli Lilly and Company will post 36.19 EPS for the current year.

Insider Transactions at Eli Lilly and Company In related news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the transaction, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. This represents a 29.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of Eli Lilly and Company stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 13,500 shares of company stock worth $15,958,170 over the last quarter. 0.14% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades LLY has been the subject of several research reports. Leerink Partners lifted their price objective on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Royal Bank Of Canada reiterated an “outperform” rating and set a $1,500.00 target price on shares of Eli Lilly and Company in a report on Monday. Bank of America increased their target price on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a report on Friday, July 10th. Morgan Stanley raised their price target on Eli Lilly and Company from $1,419.00 to $1,430.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. Finally, UBS Group set a $1,376.00 price target on Eli Lilly and Company in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, twenty-five have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $1,313.43.

Check Out Our Latest Stock Report on LLY

(Free Report)

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.

Read More Five stocks we like better than Eli Lilly and Company Salesforce Just Got a Rare Double Upgrade—What Changed? OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit 3 REITs That May Win in a Higher Interest Rate Environment Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

A raised full-year outlook failed to cushion Johnson and Johnson shares from a sharp selloff, as a single line item in its earnings release sent reported profit into a near-total collapse and left investors weighing whether the company's bold growth…

Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) stock is at $249.55, down 5% early in the session. The company raised its full-year outlook in the same release that showed its reported profit falling under one-time charges.

Meanwhile, Eli Lilly (NYSE:LLY) stock is at $1,174.46, down 0.7%, representing a much milder decline than Johnson & Johnson stock. At the same time, Pfizer (NYSE:PFE) stock is at $28.34, down 0.2%, holding even closer to flat than Eli Lilly stock.

Sector-wide, the Health Care Select Sector SPDR ETF (NYSEARCA:XLV) is declining 1%, and both Johnson & Johnson and Eli Lilly rank among its largest holdings. For a broad-market reading, the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) is down by only 0.2%.

Talc Charge Swamps a Raised Forecast Johnson & Johnson said Q3 2026 revenue grew 5.9%, and the company raised its full-year sales and adjusted earnings forecasts. Johnson & Johnson said reported net earnings fell 95.9%, a decline it attributed to special items. Those items included a charge tied to its proposed talc litigation resolution, the acquisition of Firefly Bio and a collaboration with Sail Biomedicines.

Chairman and chief executive Joaquin Duato stated that the quarter reflected accelerating momentum and that investments in high-growth areas give the company a clearer path to double-digit growth by the end of the decade. Yet, the selloff shows the collapse in reported profit outweighing the higher targets for now.

Medicines Carry the Quarter While MedTech Lags Johnson & Johnson’s growth came from the Innovative Medicine division, led by cancer treatments including Darzalex, Carvykti and Tecvayli. MedTech, by contrast, grew far more slowly.

“Our performance is below the standard we have set internally and below the expectations we previously communicated to investors. Simply put, we can do better and we absolutely will,” Tim Schmid declared. Management pointed to weakness outside the U.S. and at Abiomed globally as the main pressure points. Procedure demand, by management’s account, remained stable across key markets.

Structurally, Johnson & Johnson runs an Innovative Medicine division selling branded prescription drugs and a MedTech division selling surgical devices, orthopedic implants and contact lenses. Eli Lilly and Pfizer carry no comparable device exposure, which is why a soft quarter in medical devices doesn’t read across to either company.

Separately, Johnson & Johnson won market authorization for its OTTAVA robotic surgical system during the quarter and secured priority review for RYBREVANT FASPRO in advanced head and neck cancer. Plans to separate the Orthopaedics business add another moving part to the device story.

Talc Relief Meets a MedTech Question Johnson & Johnson’s bull case rests on a talc resolution that removes an burden investors have carried for years. Duato’s closing pitch on the call leaned into that view: “Taken together, these drivers position Johnson & Johnson as one of the cleanest growth stories in healthcare.” Of the Abiomed slump, Schmid maintained, “We do not view these challenges as structural in nature and ones that will drive a long-term impact on the business.”

A skeptic’s case is that MedTech grew slowly enough to raise a question the medicines business doesn’t answer. Another open issue is how much deal-related expense remains, since management flagged continuing dilution from the Firefly Bio and Sail Biomedicines transactions next year.

What to Watch Next Joseph Wolk, chief financial officer at Johnson & Johnson, said the talc resolution is trending toward its required participation threshold. Johnson & Johnson’s shareholders can watch for whether MedTech growth picks up in the coming quarter as the near-term headwinds management cited begin to moderate. Wolk also noted that the company’s path to double-digit growth does not assume any inorganic additions at this point.

Until MedTech rebounds and the talc deal is completed, investors may want to keep their exposure to Johnson & Johnson sized for continued swings around one-time charges.

Contact [email protected] for any questions or corrections.

When stocks start trading north of the $1,000 mark, investors often wonder if a stock split may be coming. A stock split reduces the price of a stock, making it easier for investors to buy without having to purchase fractional shares, which aren't available on all platforms and for all types of stocks.

Healthcare giant Eli Lilly (LLY +0.28%) has a share price that's comfortably above $1,000, and these days is closer to the $1,200 mark. It's been a tremendous growth stock over the years, and its valuation is north of $1 trillion. A great way to cap off its impressive growth might be with a stock split before the end of the year. But here's why I don’t think that will happen.

Image source: Getty Images.

The company last did a stock split in 1997There are some companies that love to do stock splits, while others aren't nearly as keen. It's been 29 years since Eli Lilly last did a stock split, when it did a 2-for-1 split back in 1997. That was the fourth split in its history; the others took place in 1995, 1989, and 1986. For a while there, Eli Lilly seemed to love stock splits.

However, stock splits are discretionary. Management may not choose to undertake them, even if the stock price becomes incredibly high. Eli Lilly could easily do a 10-for-1 split today, and its share price would still be above $100. It hit the $1,000 mark last year, and CEO David A. Ricks, who has been at the helm since 2017, hasn't announced a stock split. If a split was going to happen, I believe it would have taken place by now.

Premium Feature

Moneyball Superscore

96/100

Today's Change

(

0.28

%) $

3.35

Current Price

$

1,182.62

Eli Lilly is a solid stock to own for the long haul, regardless of whether it does a stock splitA stock split doesn't make investors any richer. They will own more shares, but the average share price will also go down; the investment value will remain unchanged.

The good news, however, is that for investors who are willing to hang on to Eli Lilly stock for the long term, it can still be a solid buy today. It's a dominant company in the anti-obesity drug market, and its broad business can ensure it continues growing for the foreseeable future.

Although it may not be a cheap stock to own right now, it can be a solid growth investment to hang on to for years. Plus, it can generate a lot of dividend income as it has aggressively raised its payouts in recent years. Eli Lilly is the type of growth stock that investors can buy and forget about.

Eli Lilly and Company (NYSE:LLY – Get Free Report)‘s stock had its “outperform” rating reiterated by analysts at Royal Bank Of Canada in a report issued on Monday, MarketBeat reports. They currently have a $1,500.00 target price on the stock. Royal Bank Of Canada’s price objective points to a potential upside of 26.88% from the company’s current price.

Several other equities analysts have also weighed in on LLY. HSBC boosted their price objective on shares of Eli Lilly and Company from $850.00 to $940.00 and gave the stock a “reduce” rating in a report on Thursday, September 10th. Leerink Partners boosted their price objective on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a report on Thursday, June 25th. Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, August 26th. Berenberg Bank set a $1,400.00 price objective on shares of Eli Lilly and Company and gave the stock a “buy” rating in a report on Tuesday, September 15th. Finally, Bank of America boosted their price objective on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a report on Friday, July 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $1,313.43.

View Our Latest Stock Report on LLY

Eli Lilly and Company Trading Up 0.3% Shares of NYSE LLY traded up $2.95 during trading on Monday, hitting $1,182.22. 295,981 shares of the company traded hands, compared to its average volume of 2,952,853. Eli Lilly and Company has a 1 year low of $783.85 and a 1 year high of $1,292.65. The company has a 50-day moving average price of $1,174.35 and a 200-day moving average price of $1,098.33. The firm has a market capitalization of $1.11 trillion, a P/E ratio of 39.70, a P/E/G ratio of 1.47 and a beta of 0.46. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The company had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. During the same period in the previous year, the company earned $6.31 EPS. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities analysts predict that Eli Lilly and Company will post 36.19 EPS for the current year.

Insider Activity at Eli Lilly and Company In other Eli Lilly and Company news, CAO Donald Zakrowski sold 2,000 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the transaction, the chief accounting officer owned 1,526 shares in the company, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,500 shares of company stock valued at $15,958,170 in the last quarter. Insiders own 0.14% of the company’s stock.

Institutional Inflows and Outflows Several institutional investors and hedge funds have recently bought and sold shares of the company. Osbon Capital Management LLC bought a new stake in shares of Eli Lilly and Company in the fourth quarter worth $25,000. Basso Capital Management L.P. bought a new stake in shares of Eli Lilly and Company in the fourth quarter worth $30,000. Maseco LLP lifted its position in shares of Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after purchasing an additional 28 shares in the last quarter. Aventus Investment Advisors Inc. lifted its position in shares of Eli Lilly and Company by 270.0% in the first quarter. Aventus Investment Advisors Inc. now owns 37 shares of the company’s stock worth $34,000 after purchasing an additional 27 shares in the last quarter. Finally, Marshall & Sterling Wealth Advisors Inc. lifted its position in shares of Eli Lilly and Company by 60.0% in the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after purchasing an additional 15 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company News Roundup Here are the key news stories impacting Eli Lilly and Company this week:

Positive Sentiment: Royal Bank of Canada reaffirmed its “Outperform” rating and set a $1,500 price target, implying substantial upside from recent trading levels. The endorsement supports the view that Lilly’s earnings growth and obesity-drug opportunity remain attractive. Eli Lilly and Company’s Outperform Rating Reiterated at Royal Bank Of Canada Positive Sentiment: Analysts and investors continue to focus on Lilly’s expanding obesity-treatment pipeline. A reported drug combination produced significantly greater weight loss than Zepbound alone, potentially pointing to stronger future efficacy and additional commercial opportunities. Drug Combination Generated More Weight Loss Than Zepbound Neutral Sentiment: The combination’s higher discontinuation rate is a notable limitation. While the stronger weight-loss results are encouraging, Lilly may need to improve tolerability and patient persistence before the approach can materially increase revenue or valuation. Drug Combination Results and Discontinuation Rates Negative Sentiment: Lilly’s recent roughly 8% retreat appears linked mainly to profit-taking and concerns about taking profits ahead of 2027, rather than weakening demand. Copycat versions of retatrutide and other competitive threats could nevertheless pressure future pricing, market share, or investor sentiment. Eli Lilly Takes on Retatrutide Copycats (Get Free Report)

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.

Featured Stories Five stocks we like better than Eli Lilly and Company 3 REITs That May Win in a Higher Interest Rate Environment Broadcom’s Anthropic Bet Gets Bigger as $60 Billion Financing Raises the Stakes Insider Buying Signals Opportunity in H.B. Fuller, FocalTherics, Cardinal 5 Retail Picks to Watch as the Holiday Shopping Season Nears

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.